var title_f11_34_11808="Primary chylopericardium CT";
var content_f11_34_11808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary chylopericardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan from a patient with primary chylopericardium. The thoracic duct (large white arrow) is connected to the pericardial cavity (small arrow heads).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from: Akamatsu H, Amano J, Sakamoto T, Suzuki A. Ann Thorac Surg 1994; 58:262.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11808=[""].join("\n");
var outline_f11_34_11808=null;
var title_f11_34_11809="Enoximone: International drug information";
var content_f11_34_11809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enoximone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cardomel (ES);",
"     </li>",
"     <li>",
"      Perfan (BE, DE, GB, IE, IT, NL);",
"     </li>",
"     <li>",
"      Perfane (FR, IT, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phosphodiesterase Enzyme Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of congestive heart failure",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Slow I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justified;\">",
"     Initial: 0.5-1 mg/kg, then 500 mcg/kg every 30 minutes until satisfactory response or total of 3 mg/kg given",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justified;\">",
"     Maintenance: Initial dose of up to 3 mg/kg may be repeated every 3-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     I.V. infusion: Initial: 90 mcg/kg/minute over 10-30 minutes, followed by continuous or intermittent infusion of 5-20 mcg/kg/minute; maximum dose: 24 mg/kg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: 5 mg/mL (20 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10376 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11809=[""].join("\n");
var outline_f11_34_11809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304076\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978683\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978686\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978682\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821164\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978685\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10376\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10376|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11810="Patient information: Diabetic retinopathy (The Basics)";
var content_f11_34_11810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15847\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28465\">",
"         Common eye disorders",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/57/13201\">",
"          How diabetic retinopathy affects vision",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/11/24754\">",
"         Patient information: Age-related macular degeneration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11826\">",
"         Patient information: Age-related vision loss (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6114\">",
"         Patient information: Cataracts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2258\">",
"         Patient information: Glaucoma (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diabetic retinopathy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/diabetic-retinopathy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10100363\">",
"      <span class=\"h1\">",
"       What is diabetic retinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diabetic retinopathy is an eye problem that can lead to vision loss and even blindness. It affects people with diabetes. It is most common in people who do not control their blood sugar well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10100370\">",
"      <span class=\"h1\">",
"       What are the symptoms of diabetic retinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with diabetic retinopathy have no symptoms until the disease is very advanced. By then, it is usually too late to do anything about the vision loss. That&rsquo;s why it is important to get screened for the condition early. That way, doctors can take steps to protect your eyes before your vision is damaged.",
"     </p>",
"     <p>",
"      When symptoms start, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blurry vision",
"       </li>",
"       <li>",
"        Dark or floating spots (",
"        <a class=\"graphic graphic_picture graphicRef63624 \" href=\"UTD.htm?12/57/13201\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Trouble seeing things that are at the center of your focus when reading or driving",
"       </li>",
"       <li>",
"        Trouble telling colors apart",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10100377\">",
"      <span class=\"h1\">",
"       Is there a test for diabetic retinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for diabetic retinopathy, eye doctors can do 1 of 2 main tests:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Dilated eye exam",
"        </strong>",
"        &mdash; During this exam, the eye doctor gives you eye drops to make your pupils open up. (The drops make it easier for the doctor to see the different parts of the inside of your eye.) After the drops have done their job, the doctor looks at the back of your eye, called the retina. That&rsquo;s the part of the eye that is damaged by diabetic retinopathy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Digital retinal imaging",
"        </strong>",
"        &mdash; For this test, a technician takes pictures of the eye with a special camera. Then he or she sends the pictures to an eye doctor, who checks for disease. It is OK to use this test if your past eye tests have all been normal or if you have no eye doctors nearby. Otherwise, you should have a dilated eye exam.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If either the dilated eye exam or the digital retinal imaging test shows a problem, the eye doctor might suggest other tests, too.",
"     </p>",
"     <p>",
"      All people with diabetes should have their eyes checked every year. Ideally, the checkup should include a dilated eye exam done by an eye doctor. (People who have had normal eye exams in the past and do not have an eye doctor nearby can instead have digital retinal imaging.)",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        For people with type 1 diabetes, yearly eye exams should start 3 to 5 years after diagnosis.",
"       </li>",
"       <li>",
"        For people with type 2 diabetes, yearly eye exams should start right after diagnosis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10100384\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you notice any vision loss (or dark spots in your vision), see an eye doctor as soon as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10100391\">",
"      <span class=\"h1\">",
"       How is diabetic retinopathy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When mild, diabetic retinopathy is not always treated. But people with the condition do need to keep their blood sugar and blood pressure levels as close to normal as possible. This helps keep the condition from getting worse. &nbsp;",
"     </p>",
"     <p>",
"      Treatments for diabetic retinopathy can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Photocoagulation",
"        </strong>",
"        &mdash; This is laser surgery to seal or destroy leaking or growing blood vessels in the retina.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Vitrectomy",
"        </strong>",
"        &mdash; This is surgery to remove blood from the part of the eye called the &ldquo;vitreous humor&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef76735 \" href=\"UTD.htm?27/51/28465\">",
"         figure 1",
"        </a>",
"        ). Doctors do this surgery if the blood vessels in the retina leak into the vitreous humor.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10100398\">",
"      <span class=\"h1\">",
"       Can diabetic retinopathy be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have diabetes, you can reduce your chances of getting diabetic retinopathy by keeping your blood sugar and blood pressure levels as close to normal as possible. It might also be important to keep cholesterol levels in the normal range.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10100405\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       Patient information: Age-related vision loss (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=see_link\">",
"       Patient information: Age-related macular degeneration (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=see_link\">",
"       Patient information: Cataracts (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=see_link\">",
"       Patient information: Glaucoma (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/34/11810?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15847 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11810=[""].join("\n");
var outline_f11_34_11810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100363\">",
"      What is diabetic retinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100370\">",
"      What are the symptoms of diabetic retinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100377\">",
"      Is there a test for diabetic retinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100384\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100391\">",
"      How is diabetic retinopathy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100398\">",
"      Can diabetic retinopathy be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100405\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28465\">",
"      Common eye disorders",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/57/13201\">",
"       How diabetic retinopathy affects vision",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=related_link\">",
"      Patient information: Age-related macular degeneration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=related_link\">",
"      Patient information: Cataracts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=related_link\">",
"      Patient information: Glaucoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11811="Ultrasound view needle";
var content_f11_34_11811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Ultrasound view of penetrating needle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Transverse (short-axis) view of vein with penetrating needle. B) Longitudinal (long-axis) view of vein with penetrating needle. Turning the transducer 90 degrees clockwise or counterclockwise will move from one view to the other.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kost SI. Ultrasound-assisted venous access. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11811=[""].join("\n");
var outline_f11_34_11811=null;
var title_f11_34_11812="Vitamin A: Patient drug information";
var content_f11_34_11812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin A: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/59/24502?source=see_link\">",
"     see \"Vitamin A: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/11/26805?source=see_link\">",
"     see \"Vitamin A: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-25 [OTC];",
"     </li>",
"     <li>",
"      A-Natural [OTC];",
"     </li>",
"     <li>",
"      A-Natural-25 [OTC];",
"     </li>",
"     <li>",
"      Aquasol A&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691536",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat vitamin A deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703132",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vitamin A or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Higher doses of this drug may cause birth defects. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12152 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11812=[""].join("\n");
var outline_f11_34_11812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234440\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023023\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023025\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023024\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023029\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023030\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023032\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023027\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023028\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023033\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023034\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/59/24502?source=related_link\">",
"      Vitamin A: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/11/26805?source=related_link\">",
"      Vitamin A: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11813="Sys masto BM stained for ckit";
var content_f11_34_11813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow biopsy from a patient with systemic mastocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mast cells stain for the presence of c-kit, the receptor for stem cell factor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mariana C Castells, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11813=[""].join("\n");
var outline_f11_34_11813=null;
var title_f11_34_11814="Incomplete (atypical) Kawasaki disease";
var content_f11_34_11814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Incomplete (atypical) Kawasaki disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11814/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11814/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11814/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11814/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11814/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11814/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11814/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/34/11814/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6516015\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD, also called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/1\">",
"     1",
"    </a>",
"    ]. KD also occurs rarely in adults. It is typically a self-limited condition, with fever and manifestations of acute inflammation lasting for an average of 11 days without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/2\">",
"     2",
"    </a>",
"    ]. However, complications such as coronary artery aneurysms may develop and lead to significant morbidity and mortality.",
"   </p>",
"   <p>",
"    Children suspected of having KD who do not fulfill diagnostic criteria (ie, have less than four signs of mucocutaneous inflammation) may have incomplete or atypical KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. \"Incomplete\" KD is the preferred term, since these patients do not appear to differ from those with classic KD in any way except that they lack a sufficient number of criteria to fulfill the epidemiologic case definition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/2\">",
"     2",
"    </a>",
"    ]. Children with incomplete KD are also at risk for cardiovascular sequelae.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and criteria for treatment of incomplete KD are discussed in this review. Unique features in infants and adults are also presented. Other aspects of Kawasaki disease are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=see_link\">",
"     \"Kawasaki disease: Epidemiology and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16183?source=see_link\">",
"     \"Kawasaki disease: Complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5147168\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of incomplete KD is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In a retrospective report of 242 Japanese children with KD treated at a single center over a nine-year period, 10 percent of patients were diagnosed with incomplete KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence appears to be greater in infants younger than six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This was illustrated in a retrospective review of 44 children with KD; 5 of 11 infants (45 percent) had incomplete disease compared with 4 of 33 (12 percent) older children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509270\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION OF TYPICAL VERSUS INCOMPLETE KD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms appear to parallel those in children who fulfill diagnostic criteria for typical disease (",
"    <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"     table 1",
"    </a>",
"    ) when clinical judgment of reliable observers is used to define incomplete KD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H2#H2\">",
"     \"Kawasaki disease: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2509305\">",
"     'Infants'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One report studied 242 patients hospitalized for KD in Japan during a nine-year period and found that 25 (10 percent) ultimately failed to meet diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/4\">",
"     4",
"    </a>",
"    ]. Three criteria were met in 17 of the 25 patients (68 percent), and 7 (28 percent) met only two criteria. Only one patient ultimately developed transient dilatation of a coronary artery. In this review, comparison of physical findings among patients with typical and incomplete KD revealed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical lymphadenopathy was the cardinal manifestation most often absent in children with either complete or incomplete KD. Adenopathy was missing in up to 90 percent of children with incomplete disease versus 40 to 50 percent of those who met criteria for KD.",
"     </li>",
"     <li>",
"      Rash was not present in 50 percent of children with incomplete disease compared with 7 to 10 percent of children with typical KD.",
"     </li>",
"     <li>",
"      Peripheral extremity changes were absent in approximately 40 percent of incomplete KD cases. In comparison, only 15 percent of those with typical KD failed to develop palmar erythema, dorsal edema, or periungual desquamation.",
"     </li>",
"     <li>",
"      Mucous membrane changes were most characteristic of KD and were present in more than 90 percent of children with either typical or incomplete disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509277\">",
"    <span class=\"h1\">",
"     EVALUATION OF INCOMPLETE KD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of incomplete KD is problematic because the correct diagnosis rests upon clinical judgment and supportive laboratory findings, but remains uncertain unless the child develops coronary artery abnormalities. Other illnesses associated with fever, rash, and marked laboratory abnormalities must be carefully excluded before the label of incomplete KD is applied. Children with a variety of inflammatory and infectious conditions, including sarcoid, polyarteritis nodosa, and systemic onset juvenile idiopathic arthritis have been mislabeled as having incomplete KD prior to establishment of the correct diagnosis. The main diagnoses to exclude in adults are drug hypersensitivity reactions and toxic shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H26262883#H26262883\">",
"     \"Kawasaki disease: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H10#H10\">",
"     \"Kawasaki disease: Clinical features and diagnosis\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Heart Association (AHA) and the American Academy of Pediatrics (AAP) have established guidelines for the diagnosis, treatment, and management of KD (",
"    <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/2\">",
"     2",
"    </a>",
"    ]. These guidelines are based upon recommendations of an expert panel using data summarized above. They include an algorithm for the evaluation of incomplete KD (",
"    <a class=\"graphic graphic_algorithm graphicRef79349 \" href=\"UTD.htm?22/0/22543\">",
"     algorithm 1",
"    </a>",
"    ). The goal of adding this category of patients was to help providers identify children at risk of developing coronary artery abnormalities who would benefit from treatment for KD regardless of whether they meet diagnostic criteria. The guidelines use laboratory studies and echocardiography to aid in the diagnosis of patients whose clinical presentation is consistent with KD, but who do not meet diagnostic criteria (",
"    <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"     table 1",
"    </a>",
"    ). At any point in the evaluation, consultation with an expert is recommended if assistance is required or the diagnosis is in question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509284\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is recommended for the following patients with suspected incomplete KD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients less than six months of age with unexplained fever &ge;seven days, even if they have no clinical findings of KD.",
"     </li>",
"     <li>",
"      Patients of any age with unexplained fever &gt;five days and fewer than three clinical criteria (",
"      <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AHA/AAP",
"    </span>",
"    recommended laboratory evaluation includes the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute phase reactants (CRP or ESR)",
"     </li>",
"     <li>",
"      Complete blood count (CBC) with differential white blood cell count (WBC)",
"     </li>",
"     <li>",
"      Urinalysis",
"      <span class=\"nowrap\">",
"       (U/A),",
"      </span>",
"      preferably clean catch",
"     </li>",
"     <li>",
"      Serum alanine aminotransferase level",
"     </li>",
"     <li>",
"      Serum albumin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory findings suggestive of KD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated acute phase reactants (CRP &ge;3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or ESR &ge;40",
"      <span class=\"nowrap\">",
"       mm/hr)",
"      </span>",
"     </li>",
"     <li>",
"      White cell count",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Normocytic, normochromic anemia for age (",
"      <a class=\"graphic graphic_table graphicRef57465 \" href=\"UTD.htm?5/34/5679\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyuria (&ge;10 white blood",
"      <span class=\"nowrap\">",
"       cells/high-power",
"      </span>",
"      field)",
"     </li>",
"     <li>",
"      Serum alanine aminotransferase level &gt;50",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"     </li>",
"     <li>",
"      Serum albumin &le;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Platelet cell count",
"      <span class=\"nowrap\">",
"       &ge;450,000/microL",
"      </span>",
"      after seven days of illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509291\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cardiac abnormalities detected by echocardiography, although not included in the diagnostic criteria for KD, provides support in ambiguous (incomplete) cases of KD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link&amp;anchor=H13231738#H13231738\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Echocardiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H26262883#H26262883\">",
"     \"Kawasaki disease: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendation for echocardiography depends upon the clinical course and initial laboratory findings. Echocardiography is recommended in the following circumstances when a diagnosis of KD is under consideration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevation of CRP",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ESR and less than three supplemental abnormal laboratory findings. KD is unlikely if the echocardiogram is normal and the fever abates. Repeat echocardiography and consultation with a clinician who has expertise in KD are recommended if fever persists.",
"     </li>",
"     <li>",
"      Periungual desquamation after resolution of the fever in someone not meeting epidemiologic criteria for KD. The diagnosis is unlikely if the echocardiogram is normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiographic abnormalities suggestive of KD include aneurysms (rare before 10 days of disease), findings consistent with coronary arteritis (eg, perivascular brightness, ectasia, and lack of tapering of the coronary arteries), decreased left ventricular contractility, mild valvular regurgitation (primarily mitral valve), and pericardial effusion. However, none of these findings, including coronary artery dilatation, is pathognomonic for KD. A prospective study of echocardiograms in febrile children found that conditions other than KD can be associated with some degree of coronary artery dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/8\">",
"     8",
"    </a>",
"    ]. However, only children with KD had coronary artery z-scores &gt;2.5, suggesting that significant coronary artery enlargement is indeed a reliable marker of probable KD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509298\">",
"    <span class=\"h1\">",
"     CRITERIA FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AHA/AAP",
"    </span>",
"    criteria to diagnose incomplete KD and initiate treatment in a child with features compatible with KD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated CRP",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ESR and three or more abnormal supplemental laboratory findings (See",
"      <a class=\"local\" href=\"#H2509284\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      Abnormal echocardiography (See",
"      <a class=\"local\" href=\"#H2509291\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of KD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to recognize that as long as the diagnosis of KD is based upon clinical criteria, it will remain an imperfect undertaking. Although the above recommendations reflect the consensus of experts in the field, they are not based upon firm data, and they have not been validated. Ultimately, they reflect the bias in favor of treatment in uncertain cases that has developed as a result of having an effective and safe therapy. Children with a variety of other febrile conditions may receive IVIG treatment using these guidelines. Thus, these recommendations should be applied only as intended, in cases in which an experienced clinician considers KD to be a probable diagnosis.",
"   </p>",
"   <p>",
"    Treating children at risk even though the diagnosis is uncertain should result in fewer children with incomplete KD subsequently developing coronary artery aneurysms. This was demonstrated in a study that evaluated the performance of the 2004",
"    <span class=\"nowrap\">",
"     AHA/AAP",
"    </span>",
"    criteria in 195 children at four centers, 58 of whom developed coronary artery aneurysms despite failing to meet criteria for KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/9\">",
"     9",
"    </a>",
"    ]. Fifty-three of these children had atypical KD and would have received IVIG at presentation according to the algorithm. Two of the remaining five patients would have received IVIG after further monitoring. Overall, application of the 2004",
"    <span class=\"nowrap\">",
"     AHA/AAP",
"    </span>",
"    guidelines would have led to IVIG treatment of 97 percent of the children who developed aneurysms. The corresponding number of children without KD who would have received unnecessary IVIG treatment was not calculated. In any event, as long as the disadvantages of undertreating appear to outweigh the disadvantages of overtreating, some children who have a condition that mimics KD will receive unnecessary intravenous immune globulin (IVIG). Thus, continued consideration of alternative diagnoses in &ldquo;atypical cases&rdquo; is essential despite initial response to IVIG. This is particularly important in children who fail to respond or respond only incompletely to IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6516194\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier reports suggested a poor prognosis for infants and children with incomplete KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ]. One review cited a 41 percent mortality, although only children with coronary artery aneurysms were included in this series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/10\">",
"     10",
"    </a>",
"    ]. However, subsequent studies have indicated that outcomes in children with incomplete KD may be comparable to those of children with complete disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/12\">",
"     12",
"    </a>",
"    ]. Nonetheless, the overall data continue to suggest that children with incomplete KD are more likely to develop coronary artery abnormalities, probably because they are less likely to be diagnosed expeditiously [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In fact, the goal of the",
"    <span class=\"nowrap\">",
"     AHA/AAP",
"    </span>",
"    guidelines cited above is to remove precisely this obstacle to early diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509305\">",
"    <span class=\"h1\">",
"     INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants are more likely to present with incomplete KD, occasionally even presenting only with fever and no other clinical features of KD. Infants are also at increased risk of coronary artery (CA) aneurysms, possibly in part because of delay in treatment due to their lack of complete diagnostic criteria. Thus, infants six months of age or less with unexplained fever for at least seven days should be evaluated for KD regardless of whether they have signs of mucocutaneous inflammation, since early diagnosis and timely intervention can reduce their risk of cardiac sequelae.",
"   </p>",
"   <p>",
"    The following studies are illustrative of the presentation and cardiovascular outcome in infants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective Canadian study of 44 children with KD, 5 of 11 infants (45 percent) had atypical disease compared with 4 of 33 (12 percent) older children [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, all five infants with incomplete disease developed coronary artery aneurysms.",
"     </li>",
"     <li>",
"      In a Japanese nationwide survey of 2221 children younger than five years of age with KD from 1995 to 1996, approximately one-third of the group were infants younger than one year of age. These infants had an increased risk of developing cardiac aneurysms compared with children older than one year of age (15 versus 10 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective survey of North American patients with KD, 4 of 47 children younger than 12 months of age (8.5 percent) developed cardiac abnormalities compared with 5 of 272 patients 12 months or older (1.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective Taiwanese study of 120 patients with KD, the 20 infants (defined as six months of age or less) were more likely to present with incomplete KD than patients older than six months of age (35 versus 12 percent), have coronary involvement (65 versus 19 percent), and receive late immunoglobulin therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6520114\">",
"    <span class=\"h1\">",
"     ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;KD occurs rarely in adults and presents in an incomplete form more often than in children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/7,18-23\">",
"     7,18-23",
"    </a>",
"    ]. About one-fourth of adult KD cases have occurred in patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/20\">",
"     20",
"    </a>",
"    ]. One review found that cervical lymphadenopathy, hepatitis, and arthralgia were all more common in adults with KD than in children, and meningitis, thrombocytosis, and coronary artery aneurysms were less common [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/22\">",
"     22",
"    </a>",
"    ]. Splenomegaly and elevated serum ferritin levels were reported in one adult patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11814/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509312\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kawasaki disease is typically a self-limited condition, but cardiac complications can lead to significant morbidity and mortality. Timely diagnosis and initiation of appropriate therapy minimize cardiac sequelae and improve clinical outcome. (See",
"      <a class=\"local\" href=\"#H6516015\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"       \"Cardiovascular sequelae of Kawasaki disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      KD is a systemic illness characterized by fever, conjunctivitis, mucositis, rash, extremity changes, and cervical lymphadenopathy. These findings are the basis for the diagnostic criteria for KD (",
"      <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"       table 1",
"      </a>",
"      ). Patients who lack a sufficient number of findings to fulfill the classic criteria may have incomplete KD (",
"      <a class=\"graphic graphic_algorithm graphicRef79349 \" href=\"UTD.htm?22/0/22543\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2509270\">",
"       'Clinical presentation of typical versus incomplete KD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H2#H2\">",
"       \"Kawasaki disease: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No laboratory or cardiac studies are included among the diagnostic criteria for typical KD, but certain findings characteristic of KD may support the diagnosis in ambiguous cases. (See",
"      <a class=\"local\" href=\"#H2509277\">",
"       'Evaluation of incomplete KD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H10#H10\">",
"       \"Kawasaki disease: Clinical features and diagnosis\", section on 'Laboratory findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link&amp;anchor=H13231738#H13231738\">",
"       \"Cardiovascular sequelae of Kawasaki disease\", section on 'Echocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The criteria to diagnose incomplete KD and initiate treatment in a child with features compatible with KD include elevated C-reactive protein",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erythrocyte sedimentation rate and three or more abnormal supplemental laboratory findings OR abnormal echocardiography. (See",
"      <a class=\"local\" href=\"#H2509298\">",
"       'Criteria for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and adults are more likely to present with incomplete KD. Infants are at greater risk for cardiovascular sequelae, possibly due in part to a delay in diagnosis and intervention. Thus, infants six months of age or less with unexplained fever for at least seven days should be evaluated for KD, even if they have no clinical findings of KD. (See",
"      <a class=\"local\" href=\"#H2509305\">",
"       'Infants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6520114\">",
"       'Adults'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/1\">",
"      Burns JC, Glod&eacute; MP. Kawasaki syndrome. Lancet 2004; 364:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/2\">",
"      Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/3\">",
"      Cimaz R, Sundel R. Atypical and incomplete Kawasaki disease. Best Pract Res Clin Rheumatol 2009; 23:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/4\">",
"      Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994; 83:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/5\">",
"      Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med 1995; 162:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/6\">",
"      Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995; 126:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/7\">",
"      Gomard-Mennesson E, Landron C, Dauphin C, et al. Kawasaki disease in adults: report of 10 cases. Medicine (Baltimore) 2010; 89:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/8\">",
"      Bratincsak A, Reddy VD, Purohit PJ, et al. Coronary artery dilation in acute Kawasaki disease and acute illnesses associated with Fever. Pediatr Infect Dis J 2012; 31:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/9\">",
"      Yellen ES, Gauvreau K, Takahashi M, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 2010; 125:e234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/10\">",
"      Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J 1990; 9:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/11\">",
"      Burns JC, Wiggins JW Jr, Toews WH, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986; 109:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/12\">",
"      Cho MA, Choi YJ, Jung JW. Affects of \"age at diagnosis\" on coronary artery lesions in patients with incomplete kawasaki disease. Korean Circ J 2010; 40:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/13\">",
"      Sonobe T, Kiyosawa N, Tsuchiya K, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int 2007; 49:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/14\">",
"      Sudo D, Monobe Y, Yashiro M, et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur J Pediatr 2012; 171:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/15\">",
"      Yanagawa H, Tuohong Z, Oki I, et al. Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease. Pediatr Cardiol 1999; 20:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/16\">",
"      Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998; 17:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/17\">",
"      Chang FY, Hwang B, Chen SJ, et al. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 2006; 25:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/18\">",
"      Sbidian E, Lacert A, Perrin P, Le Cleach L. [Adult Kawasaki disease]. Ann Dermatol Venereol 2009; 136:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/19\">",
"      Seeberg KA, Selbekk BH. [A man presenting with fever and abdominal pain]. Tidsskr Nor Laegeforen 2010; 130:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/20\">",
"      S&egrave;ve P, Lega JC. [Kawasaki disease in adult patients]. Rev Med Interne 2011; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/21\">",
"      Everett ED. Mucocutaneous lymph node syndrome (Kawasaki disease) in adults. JAMA 1979; 242:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/22\">",
"      Wolff AE, Hansen KE, Zakowski L. Acute Kawasaki disease: not just for kids. J Gen Intern Med 2007; 22:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11814/abstract/23\">",
"      Cunha BA, Pherez FM, Alexiadis V, et al. Adult Kawasaki's disease with myocarditis, splenomegaly, and highly elevated serum ferritin levels. Heart Lung 2010; 39:164.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15689 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11814=[""].join("\n");
var outline_f11_34_11814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2509312\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6516015\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5147168\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2509270\">",
"      CLINICAL PRESENTATION OF TYPICAL VERSUS INCOMPLETE KD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2509277\">",
"      EVALUATION OF INCOMPLETE KD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2509284\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2509291\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2509298\">",
"      CRITERIA FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6516194\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2509305\">",
"      INFANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6520114\">",
"      ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2509312\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/15689\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15689|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/0/22543\" title=\"algorithm 1\">",
"      Dx incomplete KD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15689|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/48/3851\" title=\"table 1\">",
"      Dx criteria KD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/34/5679\" title=\"table 2\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16183?source=related_link\">",
"      Kawasaki disease: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11815="Rapid response systems";
var content_f11_34_11815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid response systems",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11815/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11815/contributors\">",
"     Michael D Howell, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11815/contributors\">",
"     Jennifer P Stevens, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11815/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11815/contributors\">",
"     Tejal K Gandhi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11815/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11815/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/34/11815/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2202676\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid response systems identify deteriorating hospitalized patients prospectively and seek to alter their clinical trajectory through increasing the clinical resources directed to them [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/1\">",
"     1",
"    </a>",
"    ]. As hospitalized patients may exhibit warning signs prior to deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], rapid response systems have the potential to prevent adverse clinical outcomes, including cardiac arrest and death.",
"   </p>",
"   <p>",
"    Rapid response systems are being utilized increasingly throughout the world, particularly in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/4\">",
"     4",
"    </a>",
"    ]. In 2005, the Institute for Healthcare Improvement made implementation of rapid response systems a key part of the 100,000 Lives Campaign to improve the quality of care in hospitals and reduce mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the evidence supporting rapid response systems is limited, and it remains controversial whether these systems of care are effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this topic, we discuss the rationale for rapid response systems and current evidence for their use in adults. Rapid response systems in the pediatric population and specific treatments in the management of critically ill patients are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link&amp;anchor=H1302189#H1302189\">",
"     \"Guidelines for pediatric advanced life support\", section on 'Rapid response teams'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26712276\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid response systems are programs that are designed to improve the safety of hospitalized patients whose condition is deteriorating quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/8\">",
"     8",
"    </a>",
"    ]. They are based on prospective identification of high-risk patients, early notification of a team of responders who have been preselected and trained, rapid intervention by the response team, and ongoing evaluation of the system&rsquo;s performance.",
"   </p>",
"   <p>",
"    Several terms are used to refer to rapid response systems. These terms include critical care outreach, medical emergency teams, medical response teams, and rapid response teams. There are subtle differences between these terms, but all maintain two key features: an afferent limb (ie, how the team is activated) and an efferent limb (ie, the response of the team). Medical emergency teams typically refer to physician-led teams that have the ability to manage complex airway issues, establish central access, and initiate intensive care unit (ICU) level care at the bedside [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/8\">",
"     8",
"    </a>",
"    ]. Rapid response teams are generally nurse-led teams [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/8\">",
"     8",
"    </a>",
"    ]. Critical care outreach is slightly different from the other terms in that critical care outreach also focuses on educating non-critical care staff and improving transfers between ICUs and the general hospital wards. &nbsp;",
"   </p>",
"   <p>",
"    There are no studies to date that compare different models to one another. Each model has different advantages and disadvantages. As an example, physician-led groups may have more clinical resources immediately available to them but may be more expensive to establish, while nurse-led groups might be more immediately accessible to the bedside nurse who activates the rapid response system but require additional consultants for complicated procedures such as intubation (",
"    <a class=\"graphic graphic_table graphicRef76672 \" href=\"UTD.htm?11/15/11516\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26712442\">",
"    <span class=\"h1\">",
"     KEY COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international consensus group was convened by members of patient safety, critical care medicine, and hospital management organizations to clarify designs of rapid response systems and make recommendations for their implementation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/8\">",
"     8",
"    </a>",
"    ]. Key features of rapid response systems include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The criteria for activation are usually objective, often with at least one subjective criterion. Objective criteria usually include changes in vital signs or acute neurologic change. The subjective criterion usually involves language, such as &ldquo;Staff member is worried about the patient&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/10\">",
"       10",
"      </a>",
"      ]. The subjective criterion provides an opportunity for clinical judgment to trigger an escalation of care in the absence of vital sign or neurologic change. Inclusion of a subjective criterion has been shown to identify patients who would otherwise be missed by the objective criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/11\">",
"       11",
"      </a>",
"      ]. Examples of activation criteria are included in the table (",
"      <a class=\"graphic graphic_table graphicRef51671 \" href=\"UTD.htm?41/1/42013\">",
"       table 2",
"      </a>",
"      ). Hospitals that implement rapid response systems provide frequent reminders to all staff about the activation criteria, including placing posters around the hospital and stickers on identification badges.",
"     </li>",
"     <li>",
"      The triggering mechanism for activation must be available 24 hours a day and lead to a first response within 15 minutes. The response must be a direct examination and assessment of the patient by team members. There should be no negative feedback for activation. Typically these systems are reactive (responding to calls), but some designs include active (prospective) surveillance of triggers for patient deterioration.",
"     </li>",
"     <li>",
"      The different members of the rapid response team are generally tailored to the institution&rsquo;s specific goals, the patient&rsquo;s severity of illness, and the institution&rsquo;s resources. The members of the rapid response teams and traditional &ldquo;code&rdquo; or cardiac arrest teams can be similar, often including at least one nurse and one physician. However, in rapid response teams, the ICU personnel tend to be involved earlier in the patient&rsquo;s course than with traditional cardiac arrest teams. Regardless, any design of the rapid response system should include team members with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ability to diagnosis the clinical problem",
"     </li>",
"     <li>",
"      Ability to initiate therapy",
"     </li>",
"     <li>",
"      Authority to transfer the patient to higher levels of care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rapid response system should also have a feedback loop that collects data and ensures a response to maximize patient safety. This occurs at the patient level where a review of patient data is used to develop strategies to prevent clinical worsening, as well as at the administrative level, where resources are coordinated to provide adequate staffing, equipment, and training for the entire system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3234271\">",
"    <span class=\"h1\">",
"     GOALS OF INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goal of rapid response systems is to react promptly and appropriately to deteriorating clinical status, such as respiratory failure, cardiac failure, altered consciousness, hypotension, arrhythmias, pulmonary edema, and sepsis. Rapid response systems aim to achieve this by matching increasing patient acuity with increased health care resources and expertise at a point when disease trajectory can still be modified. Failure to recognize and respond to these conditions is associated with adverse events and is labeled &ldquo;failure to rescue.&rdquo;",
"   </p>",
"   <p>",
"    Other specific goals of care of a given system vary substantially from one institution to another. The concept of a rapid response system and its goals are summarized in a figure (",
"    <a class=\"graphic graphic_figure graphicRef58952 \" href=\"UTD.htm?13/41/13968\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2330300\">",
"    <span class=\"h2\">",
"     Identify patients at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid response teams differ from traditional cardiac arrest teams in that rapid response teams assess patients in whom respiratory, cardiac, or neurologic deterioration is developing (eg, vital sign changes or altered mental status), whereas traditional cardiac arrest teams generally respond to more downstream events, including respiratory or cardiac arrest. However, survival of inpatients with cardiac arrest is low; several studies using different methodologies indicate that the risk of death is greater than 80 percent after in-hospital cardiopulmonary resuscitation (CPR) for cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Rapid response systems are put in place to intervene before cardiac arrest and prevent deterioration.",
"   </p>",
"   <p>",
"    In multicenter, prospective cohorts, clinical antecedents, such as a change in vital signs, are present in the majority of patients (60 to 70 percent) before in-hospital cardiac arrest occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In one large prospective study, the presence of any one of the following was associated with a 6.8 fold increase in mortality (95% CI 2.7-17.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bradycardia &lt;30",
"      <span class=\"nowrap\">",
"       beats/minute",
"      </span>",
"     </li>",
"     <li>",
"      Systolic blood pressure &lt;90 mmHg",
"     </li>",
"     <li>",
"      Oxygen saturation &lt;90 percent",
"     </li>",
"     <li>",
"      Respiratory rate &lt;6",
"      <span class=\"nowrap\">",
"       breaths/minute",
"      </span>",
"     </li>",
"     <li>",
"      A decrease in Glasgow Coma Scale by 2 points",
"     </li>",
"     <li>",
"      Onset of coma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal thresholds for activation criteria in different patient populations are not well-established. In addition, it is not known what proportion of hospitalized patients have abnormal vital signs but do not go on to have an adverse event. However, patients in whom rapid response systems are activated have substantial risks for death in the short term. As an example, in one study, 18.6 percent of patients seen by the rapid response team died during the hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/15\">",
"     15",
"    </a>",
"    ]. Another study found that patients who met activation criteria had a 7.9 percent 30-day mortality rate and 15.8 percent died by 180 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2330316\">",
"    <span class=\"h2\">",
"     Communicate change in patient status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid response systems mandate and accelerate communication among team members caring for the patient. The literature suggests that a sizable percentage of cardiac arrests occur due in part due to poor communication. In one study, four independent reviewers assessed pre-arrest care of 118 inpatient cardiac arrests in a large public hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/17\">",
"     17",
"    </a>",
"    ]. The panel determined that 68 percent of cardiac arrests were avoidable. Of the avoidable cases, 35 percent had a delay in nursing staff communicating with the physician, and 29 percent had a delay in the physician responding to the nurse&rsquo;s request.",
"   </p>",
"   <p>",
"    Rapid response systems improve communication among a team of providers caring for the patient at both the nursing and physician levels by systematic activation of a team of providers and ensuring no negative feedback for appropriate activation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2330332\">",
"    <span class=\"h2\">",
"     Provide effective and timely interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quality of care of critically ill patients prior to ICU transfer may be suboptimal and associated with increased hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/18\">",
"     18",
"    </a>",
"    ]. Common causes of suboptimal care include lack of knowledge or experience by the treating clinician, failure to appreciate urgency, and failure to seek advice. As an example, in 45 percent of cases of preventable cardiac arrest in one hospital, a physician in training was the most senior physician to review clinical signs of deterioration during the 24 hours prior to cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although physicians in training are frequently involved in the care of patients by a rapid response team, specialty-trained physicians (eg, critical care specialists, cardiologists) may be systematically involved sooner than with traditional models of care, while also encouraging less-specialized providers to seek help when needed. Ideally, members of a rapid response team are also regularly trained, audited, and may undergo simulation training which improves performance both as a team and as individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289297320\">",
"    <span class=\"h2\">",
"     Avoid delays in ICU transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid response systems facilitate early transfer of patients to the ICU when needed, with less likelihood of being &ldquo;refused&rdquo; admission by the ICU service.",
"   </p>",
"   <p>",
"    Delays in ICU transfer are common, occurring in 39 percent of patients in one prospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/18\">",
"     18",
"    </a>",
"    ]. Observational studies have found that mortality rates are higher when patient transfer to higher levels of care is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one study, there was a 36 percent mortality rate in patients &ldquo;refused&rdquo; by the ICU compared to 14 percent of those admitted, a difference that persisted after adjustment for severity of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/19\">",
"     19",
"    </a>",
"    ]. In another study, patients with vital sign abnormalities greater than four hours prior to ICU transfer had an increased mortality risk compared to those who were transferred more quickly (RR 3.5, 95% CI 1.4-9.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, some critically ill patients are either inappropriately admitted to the general ward, rather than to the ICU, from the emergency room or decompensate rapidly shortly after admission. Patients transferred to the ICU within 24 hours of ward admission from the emergency department had an increased risk of 30 day mortality, compared to similar patients directly admitted to the ICU (RR 2.5, 95% CI 1.2-5.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/21\">",
"     21",
"    </a>",
"    ]. Rapid response systems can expedite ICU admission of critically ill patients from the emergency department and those who are inappropriately sent to the general ward [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289297371\">",
"    <span class=\"h1\">",
"     ROLES OF THE RAPID RESPONSE TEAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid response teams initiate specific interventions depending on the individual condition of the patient, similar to traditional cardiac arrest teams except at an earlier stage of physiological instability [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/8\">",
"     8",
"    </a>",
"    ]. Common interventions in a specific clinical situation may include administration of oxygen, intravenous fluids, bronchodilators, diuretics, and respiratory therapy (eg, suction, chest percussion with postural drainage), among others. Patients who are more acutely ill may need more aggressive treatment such as cardiopulmonary resuscitation (CPR), vasopressors, and intubation with mechanical ventilation.",
"   </p>",
"   <p>",
"    Many patients for whom the rapid response team is activated may remain on the general ward with more frequent monitoring. Others will require prompt transfer to the ICU. The rate of ICU transfer has varied widely in studies. As an example, one study found that 15 percent of patients were transferred to the ICU after a rapid response team activation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/10\">",
"     10",
"    </a>",
"    ] while, in another study, 45 percent of patients with rapid response team activations were transferred to the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Some rapid response systems (eg, critical care outreach) also facilitate communication between providers of the general wards and the ICUs during handoffs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/23\">",
"     23",
"    </a>",
"    ]. Rapid response systems may also facilitate discussion and implementation of end-of-life care [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For other patients, particularly those patients who remain on the medical ward, activation of the rapid response system may serve to realign nursing staffing. In many cases, nurse managers or other senior, experienced nurses serve as team members to both provide guidance to more junior nursing staff and to facilitate changes in staffing needs. The rapid response system serves as a marker of patients who require additional nursing staffing needs and clinician vigilance.",
"   </p>",
"   <p>",
"    Given the heterogeneity of rapid response models in the literature, there are no consistent models or recommendations for how much responsibility the rapid response team should assume in the care of the patient. In some models, the rapid response team assumes primary control over the patient&rsquo;s care, while in other hospitals, the team functions as a consult service. Some teams mandate discussion with the attending physician responsible for the patient&rsquo;s care. &nbsp;It is unclear which, if any, is the best model to prevent patient harm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2330355\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that rapid response systems are associated with lower rates of cardiac arrest, but data are limited showing mortality benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/10,23,25-27\">",
"     10,23,25-27",
"    </a>",
"    ]. Many of these studies are difficult to compare given the substantial variability in the types of rapid response systems under investigation, particularly with regard to team structure, participants, and capabilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2330464\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains unclear if implementation of rapid response systems has an effect on hospital mortality. Some cohort studies have found that rapid response systems are associated with decreased hospital mortality in pre- and post-intervention comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/10,26\">",
"     10,26",
"    </a>",
"    ], whereas others have found no difference in mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/15,28,29\">",
"     15,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only two randomized trials have evaluated rapid response systems, both with unblinded designs and conflicting findings on overall mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MERIT investigators enrolled 125,132 patients from 23 Australian hospitals in a cluster-randomized trial of medical emergency team implementation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/27\">",
"       27",
"      </a>",
"      ]. Hospitals were randomly assigned to medical emergency teams or usual care. There was no detectable difference in unexpected mortality, cardiac arrests, or unplanned ICU admissions. However, interpretation of this trial is complicated by several factors. The intervention arm hospitals had low rates of activation of the medical emergency teams, biasing their results toward negative findings. Within the intervention hospitals, 611 patients had unplanned ICU admissions with half of these patients exhibiting vital sign abnormalities for over 15 minutes before the ICU transfer. These vital sign abnormalities should have mandated a call to the medical emergency team. However, in only 95 cases (30 percent) was the medical emergency team activated. In addition, for unknown reasons, there was a 17 percent improvement in the primary outcome (a composite outcome of unexpected mortality, cardiac arrest, or unplanned ICU admission) in the control hospitals during the study period. It is unclear whether this represented improvement related to other interventions, contamination between the intervention and control groups, or was simply a chance finding.",
"     </li>",
"     <li>",
"      In a study of 2903 hospitalized patients in the United Kingdom, 16 hospital wards, in pairs matched for patient acuity and usual conditions treated, were randomly assigned in four week slots to a critical care outreach team or to usual care, with the intervention introduced to all wards by timed sequence [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/23\">",
"       23",
"      </a>",
"      ]. Implementation of the critical care outreach team reduced in-hospital mortality (OR 0.52, 95% CI 0.32-0.85). When all patients within the study period were included (not just the matched randomized ward pairs), these results were tempered to an odds ratio of 0.70 with confidence intervals nearly crossing 1.0 (95% CI 0.50-0.97). Three key limitations of this study may influence its interpretation: it was a single-site study, investigators served as both the rapid response team and collected the data in an unblinded fashion, and physiologic data and measures of severity of illness were missing for many subjects.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systematic reviews and meta-analyses of rapid response systems in adult populations have analyzed these two trials and several observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. They have generally concluded that the body of work has significant methodological issues and fails to show an improvement in mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2330363\">",
"    <span class=\"h2\">",
"     Cardiac arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that rapid response systems are associated with a reduction in cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/10,15,25,28,29,34\">",
"     10,15,25,28,29,34",
"    </a>",
"    ], even though most of the same studies did not find a reduction in overall mortality. In a meta-analysis of 17 studies including 15 observational studies and the two randomized trials discussed above, rapid response systems were associated with a reduction in cardiac arrests outside of the ICU (RR 0.7; 95% CI, 0.5-0.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these trials have focused on cardiac arrests outside of the ICU as an outcome of interest. There are two reasons for this. First, most rapid response systems do not operate in the ICU, so it is not plausible that they would affect care there. Second, one fundamental goal of rapid response systems is to move patients to higher levels of care when needed. Cardiac arrests outside the ICU occur in a location where resources are less intense than in the ICU, and therefore often represent a failure to escalate care. Patients already in the ICU cannot be transferred to a higher level of care, and it is unclear that cardiac arrests in the ICU can be prevented. Thus, many trials have focused on non-ICU cardiac arrests as an important outcome. It remains unclear from the trials why improvements in cardiac arrest rates have not translated into reductions in mortality. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289297118\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have found that rapid response systems may affect other clinical outcomes, such as postoperative complications and &nbsp;In a before-and-after study of a medical emergency team intervention in 1116 patients, there were decreased rates of respiratory failure, stroke, severe sepsis, and acute renal failure requiring renal replacement therapy after the medical emergency team was initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/10\">",
"     10",
"    </a>",
"    ]. Although a number of studies of rapid response systems, including the largest randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/27\">",
"     27",
"    </a>",
"    ], have focused an unplanned ICU transfers as an outcome to be prevented, our impression is that this is problematic. ICU transfers may well be on the causal pathway to any benefit by a rapid response system, and we would not encourage using ICU transfer as a measure to assess success of a rapid response system. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289297392\">",
"    <span class=\"h1\">",
"     POTENTIAL DISADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid response systems may have potential disadvantages. It is possible that the reliance on rapid response systems may induce a decreased sense of responsibility on the part of the hospital ward team. Hospital ward teams may be less likely to provide optimal care knowing that there is a backup system of rapid response systems to identify and treat patients if they worsen. The presence of rapid response teams may also inadvertently lead to confusion as to who has primary responsibility for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, implementation of rapid response systems can be expensive and time-consuming. It is unclear whether these systems divert resources away from more effective interventions. Because it is not clear what the optimal activation criteria are to prevent unnecessary evaluation and ICU transfer, rapid response systems may lead to excessive assessment of patients who have abnormal vital signs but are not at risk for serious adverse events. Activation criteria in several sites have focused on changes in vital signs rather than fixed values in an effort to identify deteriorating patients more accurately [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/10\">",
"     10",
"    </a>",
"    ]. However, it is our experience is that it is difficult to implement calculations at the bedside unless it is embedded in an electronic medical record.",
"   </p>",
"   <p>",
"    Finally, some authors have suggested that implementation of a rapid response system is, in essence, creating a system of rescue for patients who have been mis-triaged to lower levels of care. Alternative strategies for managing patient flow and optimizing limited critical care resources may prove more cost effective than an entirely new clinical system [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11815/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2330486\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid response systems are programs that are designed to improve the safety of hospitalized patients whose condition is deteriorating quickly. (See",
"      <a class=\"local\" href=\"#H26712276\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key components of a rapid response system include (see",
"      <a class=\"local\" href=\"#H26712442\">",
"       'Key components'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Objective and subjective activation criteria (",
"      <a class=\"graphic graphic_table graphicRef51671 \" href=\"UTD.htm?41/1/42013\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A triggering mechanism available 24 hours a day, leading to a first response within 15 minutes of activation",
"     </li>",
"     <li>",
"      Members of the rapid response team who have the ability to diagnose the clinical problem, initiate therapy promptly, and transfer the patient to higher levels of care if needed",
"     </li>",
"     <li>",
"      A feedback loop to ensure safety improvement at both the patient and administrative levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid response systems have several goals that are focused on improving the quality of patient care as soon as clinical deterioration is detected, up until the time that patients are stabilized or transferred to the intensive care unit (ICU). (See",
"      <a class=\"local\" href=\"#H3234271\">",
"       'Goals of intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited cohort and randomized trial data have not demonstrated that implementation of rapid response systems reduce mortality in hospitalized patients, but suggest that they reduce the rate of cardiopulmonary arrest. (See",
"      <a class=\"local\" href=\"#H2330355\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/1\">",
"      Jones DA, DeVita MA, Bellomo R. Rapid-response teams. N Engl J Med 2011; 365:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/2\">",
"      Schein RM, Hazday N, Pena M, et al. Clinical antecedents to in-hospital cardiopulmonary arrest. Chest 1990; 98:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/3\">",
"      Kause J, Smith G, Prytherch D, et al. A comparison of antecedents to cardiac arrests, deaths and emergency intensive care admissions in Australia and New Zealand, and the United Kingdom--the ACADEMIA study. Resuscitation 2004; 62:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/4\">",
"      Steel AC, Reynolds SF. The growth of rapid response systems. Jt Comm J Qual Patient Saf 2008; 34:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/5\">",
"      Berwick DM, Calkins DR, McCannon CJ, Hackbarth AD. The 100,000 lives campaign: setting a goal and a deadline for improving health care quality. JAMA 2006; 295:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/6\">",
"      Winters BD, Pham J, Pronovost PJ. Rapid response teams--walk, don't run. JAMA 2006; 296:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/7\">",
"      Litvak E, Pronovost PJ. Rethinking rapid response teams. JAMA 2010; 304:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/8\">",
"      Devita MA, Bellomo R, Hillman K, et al. Findings of the first consensus conference on medical emergency teams. Crit Care Med 2006; 34:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/9\">",
"      Jones D, Baldwin I, McIntyre T, et al. Nurses' attitudes to a medical emergency team service in a teaching hospital. Qual Saf Health Care 2006; 15:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/10\">",
"      Bellomo R, Goldsmith D, Uchino S, et al. Prospective controlled trial of effect of medical emergency team on postoperative morbidity and mortality rates. Crit Care Med 2004; 32:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/11\">",
"      Parr MJ, Hadfield JH, Flabouris A, et al. The Medical Emergency Team: 12 month analysis of reasons for activation, immediate outcome and not-for-resuscitation orders. Resuscitation 2001; 50:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/12\">",
"      Peberdy MA, Kaye W, Ornato JP, et al. Cardiopulmonary resuscitation of adults in the hospital: a report of 14720 cardiac arrests from the National Registry of Cardiopulmonary Resuscitation. Resuscitation 2003; 58:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/13\">",
"      Ehlenbach WJ, Barnato AE, Curtis JR, et al. Epidemiologic study of in-hospital cardiopulmonary resuscitation in the elderly. N Engl J Med 2009; 361:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/14\">",
"      Buist M, Bernard S, Nguyen TV, et al. Association between clinically abnormal observations and subsequent in-hospital mortality: a prospective study. Resuscitation 2004; 62:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/15\">",
"      Chan PS, Khalid A, Longmore LS, et al. Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA 2008; 300:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/16\">",
"      Konrad D, J&auml;derling G, Bell M, et al. Reducing in-hospital cardiac arrests and hospital mortality by introducing a medical emergency team. Intensive Care Med 2010; 36:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/17\">",
"      Hodgetts TJ, Kenward G, Vlackonikolis I, et al. Incidence, location and reasons for avoidable in-hospital cardiac arrest in a district general hospital. Resuscitation 2002; 54:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/18\">",
"      McQuillan P, Pilkington S, Allan A, et al. Confidential inquiry into quality of care before admission to intensive care. BMJ 1998; 316:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/19\">",
"      Sprung CL, Geber D, Eidelman LA, et al. Evaluation of triage decisions for intensive care admission. Crit Care Med 1999; 27:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/20\">",
"      Young MP, Gooder VJ, McBride K, et al. Inpatient transfers to the intensive care unit: delays are associated with increased mortality and morbidity. J Gen Intern Med 2003; 18:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/21\">",
"      Parkhe M, Myles PS, Leach DS, Maclean AV. Outcome of emergency department patients with delayed admission to an intensive care unit. Emerg Med (Fremantle) 2002; 14:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/22\">",
"      McGillicuddy DC, O'Connell FJ, Shapiro NI, et al. Emergency department abnormal vital sign \"triggers\" program improves time to therapy. Acad Emerg Med 2011; 18:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/23\">",
"      Priestley G, Watson W, Rashidian A, et al. Introducing Critical Care Outreach: a ward-randomised trial of phased introduction in a general hospital. Intensive Care Med 2004; 30:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/24\">",
"      Jones DA, McIntyre T, Baldwin I, et al. The medical emergency team and end-of-life care: a pilot study. Crit Care Resusc 2007; 9:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/25\">",
"      Buist MD, Moore GE, Bernard SA, et al. Effects of a medical emergency team on reduction of incidence of and mortality from unexpected cardiac arrests in hospital: preliminary study. BMJ 2002; 324:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/26\">",
"      Dacey MJ, Mirza ER, Wilcox V, et al. The effect of a rapid response team on major clinical outcome measures in a community hospital. Crit Care Med 2007; 35:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/27\">",
"      Hillman K, Chen J, Cretikos M, et al. Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial. Lancet 2005; 365:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/28\">",
"      DeVita MA, Braithwaite RS, Mahidhara R, et al. Use of medical emergency team responses to reduce hospital cardiopulmonary arrests. Qual Saf Health Care 2004; 13:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/29\">",
"      Bristow PJ, Hillman KM, Chey T, et al. Rates of in-hospital arrests, deaths and intensive care admissions: the effect of a medical emergency team. Med J Aust 2000; 173:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/30\">",
"      McGaughey J, Alderdice F, Fowler R, et al. Outreach and Early Warning Systems (EWS) for the prevention of intensive care admission and death of critically ill adult patients on general hospital wards. Cochrane Database Syst Rev 2007; :CD005529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/31\">",
"      Winters BD, Pham JC, Hunt EA, et al. Rapid response systems: a systematic review. Crit Care Med 2007; 35:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/32\">",
"      Chan PS, Jain R, Nallmothu BK, et al. Rapid Response Teams: A Systematic Review and Meta-analysis. Arch Intern Med 2010; 170:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/33\">",
"      Ranji SR, Auerbach AD, Hurd CJ, et al. Effects of rapid response systems on clinical outcomes: systematic review and meta-analysis. J Hosp Med 2007; 2:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11815/abstract/34\">",
"      Baxter AD, Cardinal P, Hooper J, Patel R. Medical emergency teams at The Ottawa Hospital: the first two years. Can J Anaesth 2008; 55:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16280 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11815=[""].join("\n");
var outline_f11_34_11815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2330486\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202676\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26712276\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26712442\">",
"      KEY COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3234271\">",
"      GOALS OF INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2330300\">",
"      Identify patients at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2330316\">",
"      Communicate change in patient status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2330332\">",
"      Provide effective and timely interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H289297320\">",
"      Avoid delays in ICU transfer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289297371\">",
"      ROLES OF THE RAPID RESPONSE TEAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2330355\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2330464\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2330363\">",
"      Cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H289297118\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289297392\">",
"      POTENTIAL DISADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2330486\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16280\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16280|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/41/13968\" title=\"figure 1\">",
"      Model for rapid response systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16280|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/15/11516\" title=\"table 1\">",
"      Rapid response team staffing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/1/42013\" title=\"table 2\">",
"      Activation criteria for rapid response systems",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11816="Malignant salivary gland tumors: Treatment of recurrent and metastatic disease";
var content_f11_34_11816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11816/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11816/contributors\">",
"     Scott A Laurie, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11816/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11816/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11816/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11816/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11816/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/34/11816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary glands produce and secrete saliva from a glandular structure, the secretory acinus, ducts, and myoepithelial and basal cells. Salivary gland tumors can be benign or malignant (",
"    <a class=\"graphic graphic_table graphicRef70453 \" href=\"UTD.htm?20/36/21069\">",
"     table 1",
"    </a>",
"    ). These tumors can arise from either the major salivary glands (parotid, submandibular, and sublingual, (",
"    <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"     figure 1",
"    </a>",
"    )) or the minor salivary glands, which are located throughout the submucosa of the mouth and upper aerodigestive tract, including the oral cavity (especially the palate), paranasal sinuses, larynx, and pharynx.",
"   </p>",
"   <p>",
"    Salivary gland tumors are rare, and information on management is based mainly upon clinical experience in retrospective series. The most common malignant salivary gland tumors include mucoepidermoid carcinoma, adenoid cystic carcinoma, polymorphous low grade adenocarcinoma, carcinoma ex pleomorphic adenoma, acinic cell carcinoma, and adenocarcinoma not otherwise specified.",
"   </p>",
"   <p>",
"    The treatment of locoregionally recurrent and metastatic salivary gland tumors is reviewed here. The initial treatment of locoregional disease and the epidemiology, risk factors, pathology, and clinical features of these tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link\">",
"     \"Salivary gland tumors: Treatment of locoregional disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264372274\">",
"    <span class=\"h1\">",
"     LOCOREGIONALLY RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for recurrent salivary gland tumors, as with recurrent head and neck cancer in general, are limited by previous therapy received and resectability of recurrent disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link\">",
"     \"Treatment of locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of recurrent pleomorphic adenoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link&amp;anchor=H17#H17\">",
"     \"Salivary gland tumors: Treatment of locoregional disease\", section on 'Pleomorphic adenoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264372590\">",
"    <span class=\"h2\">",
"     Local relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, surgical salvage is the optimal treatment for resectable recurrent salivary gland tumors, although outcomes with surgical salvage are disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If surgery is not feasible, irradiation or, in selected patients, reirradiation are treatment options for recurrent salivary gland tumors. Patient selection for reirradiation is critical, due to its toxicity and the likelihood of resistant disease in patients with tumor recurrence within six months after the first course of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link\">",
"     \"Reirradiation for locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irradiation for recurrent disease is carried out with conventional external beam radiation therapy using photons or electrons. Alternative approaches include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High linear energy transfer (LET) radiotherapy (with neutrons or carbon ions) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link&amp;anchor=H11#H11\">",
"       \"Salivary gland tumors: Treatment of locoregional disease\", section on 'Definitive treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraoperative radiation therapy (combined with salvage surgery) and brachytherapy offer additional options for salvage therapy, but are usually reserved for patients who previously received external beam radiation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link\">",
"       \"Reirradiation for locally recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy combined with local hyperthermia or concurrent chemoradiotherapy may play a role in the treatment of some locally advanced or recurrent salivary gland tumors, but experience is limited and these remain experimental approaches [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/5-8\">",
"       5-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If neither surgery nor radiation therapy are feasible, then palliative chemotherapy, as discussed below, may be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264372597\">",
"    <span class=\"h2\">",
"     Regional recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck dissection, with or without postoperative radiation therapy, is performed, if feasible, for surgical salvage of regional lymph node recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of locally recurrent head and neck cancer\", section on 'Isolated neck recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sites of distant metastatic involvement with malignant salivary gland tumors are lung, liver, and bone. While potentially curative surgical resection of a solitary site of metastasis may be considered in select cases, treatment of metastatic disease is most often palliative.",
"   </p>",
"   <p>",
"    The natural history of metastatic disease is variable, and some patients remain asymptomatic for protracted periods of time. This is especially true for adenoid cystic carcinomas, particularly when metastases are limited to the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. Although there is a wide spectrum of biologic behavior, median survival following the development of metastatic adenoid cystic carcinoma is approximately three years, substantially longer than expected for most other solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of treatment of metastatic salivary gland tumors is usually palliation, since there is no clear evidence that survival is prolonged by systemic therapy. Watchful waiting may be the most appropriate strategy for patients with indolent disease and few or no symptoms. Systemic therapy may be reserved for those with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rapid disease progression and for whom a local therapy, such as radiation or metastasectomy, is not appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial data to guide the choice of systemic therapy are limited due to the rarity of malignant salivary gland tumors. There are some phase II trials in adenoid cystic cancer, but prospective data for the other histologies are scarce. Whether chemotherapy alters the natural history metastatic salivary gland tumors, especially adenoid cystic carcinoma, is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, the primary goal of systemic therapy is palliation of disease-related symptoms.",
"   </p>",
"   <p>",
"    Limited data suggest there are differences in chemotherapy sensitivity among the histologic subtypes of salivary gland tumors. As an example, single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    appears to have activity against adenocarcinomas and mucoepidermoid carcinomas, but not adenoid cystic carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Whether there are differences with other agents or regimens is difficult to ascertain because of the small numbers of patients included in individual reports (",
"    <a class=\"graphic graphic_table graphicRef81091 \" href=\"UTD.htm?32/50/33581\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    have modest single agent activity in treating metastatic disease, with response rates between 10 and 40 percent (",
"    <a class=\"graphic graphic_table graphicRef81091 \" href=\"UTD.htm?32/50/33581\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/15,17-21\">",
"     15,17-21",
"    </a>",
"    ]. However, a systematic review failed to find sufficient activity of paclitaxel in the treatment of metastatic or locally recurrent adenoid cystic carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, single agent cisplatin had no better efficacy than mitoxantrone, vinorelbine, and epirubicin in the treatment of adenoid cystic carcinoma, but was associated with greater toxicity.",
"   </p>",
"   <p>",
"    Combination chemotherapy regimens generally result in higher response rates, but are not clearly superior in survival outcomes despite additional toxicity.",
"   </p>",
"   <p>",
"    The most commonly studied regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    administered on day 1 and repeated every 28 days (CAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/22\">",
"     22",
"    </a>",
"    ]. Reported objective response rates are 40 to 50 percent, with the duration of response ranging from three to seven months (",
"    <a class=\"graphic graphic_table graphicRef81091 \" href=\"UTD.htm?32/50/33581\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/22-28\">",
"     22-28",
"    </a>",
"    ]. There are no trials that compare CAP with single agent therapy or with other combination regimens.",
"   </p>",
"   <p>",
"    Other regimens evaluated in patients with advanced or recurrent disease include (",
"    <a class=\"graphic graphic_table graphicRef81091 \" href=\"UTD.htm?32/50/33581\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      to CAP had a 50 percent objective response rate in 16 evaluable patients, but was associated with significant toxicity, including two treatment related deaths (one from neutropenic sepsis and the other from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -related cardiotoxicity) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (PAF) resulted in objective response rates of 35 to 40 percent in patients with metastatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. Response duration was 6 to 15 months, and toxicity was tolerable.",
"     </li>",
"     <li>",
"      In one of the only randomized trials that was conducted in patients with metastatic disease, 36 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) or vinorelbine alone (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/21\">",
"       21",
"      </a>",
"      ]. Combination therapy was associated with a significantly higher complete response rate (19 versus 0 percent) and objective response rate (44 versus 20 percent), and a greater likelihood of survival beyond one year (38 versus 5 percent). Toxicity, in particular nausea and vomiting, was greater in the cisplatin-containing arm.",
"     </li>",
"     <li>",
"      Other platinum-based regimens, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/33\">",
"       33",
"      </a>",
"      ], cisplatin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/9\">",
"       9",
"      </a>",
"      ], cisplatin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/34\">",
"       34",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/35,36\">",
"       35,36",
"      </a>",
"      ], and cisplatin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/9,23,37,38\">",
"       9,23,37,38",
"      </a>",
"      ] have demonstrated moderate activity in small trials (",
"      <a class=\"graphic graphic_table graphicRef81091 \" href=\"UTD.htm?32/50/33581\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether any of these regimens provides an advantage over single agent therapy or the CAP regimen is unclear. We suggest an initial platinum and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    combination (such as CAP) if the patient is very symptomatic and the goal is to maximize the likelihood of a response. Otherwise, we suggest single agent therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (for patients with histologies other than adenoid cystic),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing understanding of the underlying molecular changes in malignant salivary gland tumors has led to the identification of several potential therapeutic targets. There are few objective responses to these agents in phase II trials, but the high rates and long duration of disease stabilization are interesting and encouraging. However, whether this reflects antitumor activity or the indolent natural history of many malignant salivary gland tumors is unclear, particularly since many trials did not require clear evidence of disease progression prior to enrollment. The data are too preliminary to recommend the routine use of any of these agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      : Approximately 90 percent of adenoid cystic carcinomas express the c-kit tyrosine kinase receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/15,39\">",
"       15,39",
"      </a>",
"      ]. However, objective responses to imatinib in phase II trials in over 60 patients with adenoid cystic carcinoma were uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/15,40\">",
"       15,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       Gefitinib",
"      </a>",
"      : The epidermal growth factor receptor (EGFR) is often overexpressed in adenoid cystic and mucoepidermoid cancers, but no responses were documented among 29 patients with metastatic disease (19 adenoid cystic cancers and 2 mucoepidermoid cancers) in a phase II trial of gefitinib, an orally active EGFR tyrosine kinase inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/41\">",
"       41",
"      </a>",
"      ]. Ten patients had disease stabilization, which was maintained for at least 16 weeks in five patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       Cetuximab",
"      </a>",
"      : Another method to target the EGFR is with anti-EGFR monoclonal antibodies such as cetuximab. No objective responses were observed in 30 patients (23 with adenoid cystic carcinoma), although 20 of the patients with adenoid cystic carcinoma had disease stabilization for a median of six months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      : Up to one-third of mucoepidermoid carcinomas and an even higher proportion of salivary duct cancers overexpress human epidermal growth factor receptor 2 (HER2), or have gene amplification as detected by fluorescence in situ hybridization [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/43-47\">",
"       43-47",
"      </a>",
"      ]. In contrast, expression of HER2 is unusual in adenoid cystic carcinomas and adenocarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/44,48\">",
"       44,48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a phase II trial of trastuzumab, an anti-HER2 monoclonal antibody, one of three patients with mucoepidermoid cancer had a partial response lasting longer than two years, while two patients with previously progressive salivary duct carcinomas had disease stabilization for 26 and 40 weeks, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/44,49\">",
"       44,49",
"      </a>",
"      ]. There are other case reports of durable responses to trastuzumab-containing chemotherapy regimens in patients with salivary duct carcinoma, suggesting that this agent is a reasonable treatment option for this very rare cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/47,50-53\">",
"       47,50-53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"      : Lapatinib, an orally active dual inhibitor of EGFR and HER2, was studied in a phase II trial of 40 patients with progressive metastatic or recurrent EGFR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HER2-overexpressing metastatic salivary gland tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/54\">",
"       54",
"      </a>",
"      ]. Although no responses were observed, 47 percent of patients treated with lapatinib had prolonged tumor stabilization of at least six months. Since disease progression prior to enrollment was required in this trial, the prolonged tumor stabilization may be more likely due to true drug effect.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      : In theory, inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) pathway by proteasome inhibitors, such as bortezomib, may serve to inhibit the growth of adenoid cystic cancers, which express NF-kappa B [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/55\">",
"       55",
"      </a>",
"      ]. In a study of bortezomib in patients with adenoid cystic carcinoma, there were no objective responses from bortezomib monotherapy, but 15 patients had disease stabilization after prior progression, with a median progression-free survival of 6.4 months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone receptor expression is virtually absent in most malignant salivary gland tumors, with the exception of androgen receptor expression in salivary duct carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/57\">",
"     57",
"    </a>",
"    ]. However, isolated case reports document objective responses in patients with adenoid cystic cancer treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], and in patients with salivary duct cancer and adenocarcinoma treated with antiandrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The data are insufficient, and the use of hormonal agents is investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Local therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, local treatment options, such as radiation or surgery, may relieve symptoms or prolong survival for select patients with metastatic salivary gland tumors.",
"   </p>",
"   <p>",
"    Long-term survival has been reported in rare patients with solitary pulmonary or hepatic metastases from metastatic salivary gland tumors, especially for patients with adenoid cystic histology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/14,62-67\">",
"     14,62-67",
"    </a>",
"    ]. As an example, in a series of 83 patients with metastatic head and neck cancer who underwent resection of pulmonary metastases, patients with metastatic adenoid cystic carcinoma had a significantly higher five-year survival than did the patients with squamous cell malignancies (84 versus 34 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/67\">",
"     67",
"    </a>",
"    ]. However, overall survival continued to decline until there were no survivors after 14 years.",
"   </p>",
"   <p>",
"    However, it is unclear that resection of metastases prolongs survival, since metastases are usually multiple and survival with adenoid cystic cancer may be prolonged without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11816/abstract/10\">",
"     10",
"    </a>",
"    ]. This strategy must be carefully considered and used selectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland tumors are rare tumors that are characterized by a variable natural history. The most common sites of distant metastatic involvement are lung, liver, and bone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For select patients with small locoregional recurrences, we suggest an aggressive approach, using surgical salvage, radiation therapy, or in selected cases, reirradiation with or without concurrent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These treatments are associated with significant toxicities, but may result in long-term survival. The decision between surgery and reirradiation is individually tailored, taking into consideration location and extent of the recurrent tumor and previous therapies. (See",
"      <a class=\"local\" href=\"#H264372274\">",
"       'Locoregionally recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with metastatic disease, the goal of treatment is palliation or prevention of symptoms. Watchful waiting may be the most appropriate strategy for apparently indolent metastatic salivary gland tumors, reserving systemic therapy for patients who are symptomatic or who have rapid disease progression. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, patients with solitary pulmonary or liver metastases may be considered for surgical resection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Local therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/1\">",
"      Dai D. Postoperative irradiation in malignant tumors of submandibular gland. Cancer Invest 1999; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/2\">",
"      M&uuml;cke T, Tannapfel A, Kesting MR, et al. Adenoid cystic carcinomas of minor salivary glands. Auris Nasus Larynx 2010; 37:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/3\">",
"      Laramore GE. Role of particle radiotherapy in the management of head and neck cancer. Curr Opin Oncol 2009; 21:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/4\">",
"      Chen AM, Garcia J, Bucci MK, et al. Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy. Head Neck 2008; 30:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/5\">",
"      Haddad RI, Posner MR, Busse PM, et al. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol 2006; 29:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/6\">",
"      Barnett TA, Kapp DS, Goffinet DR. Adenoid cystic carcinoma of the salivary glands. Management of recurrent, advanced, or persistent disease with hyperthermia and radiation therapy. Cancer 1990; 65:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/7\">",
"      Gabriele P, Amichetti M, Orecchia R, Valdagni R. Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. Cancer 1995; 75:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/8\">",
"      Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol 2010; 95:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/9\">",
"      Hill ME, Constenla DO, A'Hern RP, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997; 33:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/10\">",
"      Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 1997; 174:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/11\">",
"      Sung MW, Kim KH, Kim JW, et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2003; 129:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/12\">",
"      van der Wal JE, Becking AG, Snow GB, van der Waal I. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck 2002; 24:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/13\">",
"      Sur RK, Donde B, Levin V, et al. Adenoid cystic carcinoma of the salivary glands: a review of 10 years. Laryngoscope 1997; 107:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/14\">",
"      Yu T, Gao QH, Wang XY, et al. Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases. Oncology 2007; 72:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/15\">",
"      Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011; 12:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/16\">",
"      Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006; 28:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/17\">",
"      Licitra L, Marchini S, Spinazz&egrave; S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991; 68:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/18\">",
"      Schramm VL Jr, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 1981; 107:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/19\">",
"      Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1996; 7:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/20\">",
"      Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993; 4:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/21\">",
"      Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001; 91:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/22\">",
"      Dreyfuss AI, Clark JR, Fallon BG, et al. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 1987; 60:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/23\">",
"      Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986; 95:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/24\">",
"      Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996; 7:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/25\">",
"      Creagan ET, Woods JE, Rubin J, Schaid DJ. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 1988; 62:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/26\">",
"      Alberts DS, Manning MR, Coulthard SW, et al. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 1981; 47:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/27\">",
"      Belani CP, Eisenberger MA, Gray WC. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol 1988; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/28\">",
"      Tsukuda M, Kokatsu T, Ito K, et al. Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck. J Cancer Res Clin Oncol 1993; 119:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/29\">",
"      Dimery IW, Legha SS, Shirinian M, Hong WK. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990; 8:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/30\">",
"      Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987; 5:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/31\">",
"      Airoldi M, Pedani F, Brando V, et al. Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori 1989; 75:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/32\">",
"      Farhat F, Kattan J, Culine S, et al. [Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature]. Bull Cancer 1994; 81:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/33\">",
"      Gedlicka C, Sch&uuml;ll B, Formanek M, et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs 2002; 13:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/34\">",
"      Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 2010; 116:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/35\">",
"      Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 2000; 20:3781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/36\">",
"      Ruzich JC, Ciesla MC, Clark JI. Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Head Neck 2002; 24:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/37\">",
"      Posner MR, Ervin TJ, Weichselbaum RR, et al. Chemotherapy of advanced salivary gland neoplasms. Cancer 1982; 50:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/38\">",
"      de Haan LD, De Mulder PH, Vermorken JB, et al. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 1992; 14:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/39\">",
"      Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol 2003; 16:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/40\">",
"      Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007; 43:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/41\">",
"      Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006; 24:2673.",
"     </a>",
"    </li>",
"    <li>",
"     Licitra L, Locati LD, Potepan P, et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional phase II study (abstract). J Clin Oncol 2006; 24:291s. (Abstract available online at www.asco.org/ac/1,1003,_12-002643-00_18-0034-00_19-0031092,00.asp, accessed January 24, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/43\">",
"      Weed DT, Gomez-Fernandez C, Pacheco J, et al. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck 2004; 26:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/44\">",
"      Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004; 10:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/45\">",
"      Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005; 103:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/46\">",
"      Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994; 54:5675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/47\">",
"      Nabili V, Tan JW, Bhuta S, et al. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007; 29:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/48\">",
"      Dori S, Vered M, David R, Buchner A. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 2002; 31:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/49\">",
"      Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003; 39:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/50\">",
"      Prat A, Parera M, Reyes V, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 2008; 30:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/51\">",
"      Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol 2009; 123:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/52\">",
"      Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 2012; 29:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/53\">",
"      Limaye SA, Posner MR, Krane JF, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 2013; 18:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/54\">",
"      Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25:3978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/55\">",
"      Zhang J, Peng B, Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11:7334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/56\">",
"      Argiris A, Ghebremichael M, Burtness B, et al. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer 2011; 117:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/57\">",
"      Fan CY, Melhem MF, Hosal AS, et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001; 127:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/58\">",
"      Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol 1997; 111:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/59\">",
"      Elkin AD, Jacobs CD. Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. J Cancer Res Clin Oncol 2008; 134:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/60\">",
"      Locati LD, Quattrone P, Bossi P, et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 2003; 14:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/61\">",
"      van der Hulst RW, van Krieken JH, van der Kwast TH, et al. Partial remission of parotid gland carcinoma after goserelin. Lancet 1994; 344:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/62\">",
"      Locati LD, Guzzo M, Bossi P, et al. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol 2005; 41:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/63\">",
"      Qureshi SS, Nadkarni MS, Shrikhande SV, et al. Hepatic resection for metastasis from adenoid cystic carcinoma of parotid gland. Indian J Gastroenterol 2005; 24:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/64\">",
"      Gruttadauria S, Marino G, Catalano F, et al. Secondary carcinoma of the liver from parotid gland tumor. Chir Ital 2000; 52:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/65\">",
"      Ishihama H, Kobayashi S, Ikeda Y, et al. [Surgical treatment for pulmonary metastasis from submandibular gland cancer]. Kyobu Geka 2003; 56:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/66\">",
"      Sidhu GS, Forrester EM. Acinic cell carcinoma: long-term survival after pulmonary metastases: light and electron microscopic study. Cancer 1977; 40:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11816/abstract/67\">",
"      Liu D, Labow DM, Dang N, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol 1999; 6:572.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3382 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11816=[""].join("\n");
var outline_f11_34_11816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264372274\">",
"      LOCOREGIONALLY RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264372590\">",
"      Local relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264372597\">",
"      Regional recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3382|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6449\" title=\"figure 1\">",
"      Salivary gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21069\" title=\"table 1\">",
"      WHO class salivary gld tum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/50/33581\" title=\"table 2\">",
"      Chemo response saliv gland tum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=related_link\">",
"      Reirradiation for locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=related_link\">",
"      Salivary gland tumors: Treatment of locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11817="Glycemic control and vascular complications in type 1 diabetes mellitus";
var content_f11_34_11817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glycemic control and vascular complications in type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11817/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11817/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11817/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11817/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/34/11817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity from diabetes is a consequence of both macrovascular disease (atherosclerosis) and microvascular disease (retinopathy, nephropathy, and neuropathy). Epidemiologic studies first showed an association between poor glycemic control and microvascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This association was confirmed in the prospective Diabetes Control and Complications Trial (DCCT), which demonstrated that intensive therapy aimed at lower levels of glycemia results in decreased rates of retinopathy, nephropathy, and neuropathy in type 1 diabetes patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Similar findings have been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of tight glycemic control for protection against macrovascular disease in diabetes has also been established in the",
"    <span class=\"nowrap\">",
"     DCCT/EDIC",
"    </span>",
"    study for type 1 diabetes. In the EDIC follow-up study to the DCCT, intensive insulin therapy in patients with type 1 diabetes decreased fatal and nonfatal cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/8\">",
"     8",
"    </a>",
"    ]. The effects of glycemic control on microvascular and macrovascular complications in type 1 diabetes will be reviewed here. Glycemic control and vascular complications in type 2 diabetes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which lack of glycemic control predisposes to vascular disease is incompletely understood. Two proposed contributing factors are advanced glycosylation end products and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ; protein kinase C and other factors also may contribute (",
"    <a class=\"graphic graphic_algorithm graphicRef61356 \" href=\"UTD.htm?31/42/32430\">",
"     algorithm 1",
"    </a>",
"    ). In addition to systemic factors, organ-specific factors also appear to be important. In the kidney, for example, stimulation of mesangial matrix production by hyperglycemia, activation of protein kinase C, and an increasing degree of intraglomerular hypertension may contribute to the glomerular injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39207?source=see_link\">",
"     \"Protein kinase C and the vascular complications of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic predisposition may be another important factor. This was illustrated in a report from the DCCT in which 372 patients and 467 first-degree relatives with diabetes were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/9\">",
"     9",
"    </a>",
"    ]. Severe retinopathy was three times more frequent among the relatives of patients with retinopathy than among relatives of patients who did not have retinopathy. Familial clustering was also noted for diabetic nephropathy.",
"   </p>",
"   <p>",
"    A more in depth discussion of the pathogenesis of diabetic nephropathy, retinopathy, and neuropathy can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of diabetic nephropathy\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A causal association between glycemic control and the development and progression of the microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy) has been suggested from studies in both animals and humans. As an example, epidemiologic studies suggest that nephropathy and retinopathy are more likely to occur in patients with poorer glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The risk is highest if the hemoglobin A1C (A1C) value is above 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/4\">",
"     4",
"    </a>",
"    ], but is still increased at all values above the non-diabetic range [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/3\">",
"     3",
"    </a>",
"    ]. The severity of hyperglycemia also is correlated with recurrent diabetic nephropathy in patients who have received a renal transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These associations were confirmed in the prospective Diabetes Control and Complications Trial (DCCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/5\">",
"     5",
"    </a>",
"    ]. In this study, patients with type 1 diabetes were randomly assigned to receive either conventional therapy or intensive insulin therapy, consisting of multiple daily injections or continuous insulin administration using an insulin pump, and guided by frequent self-monitoring of blood glucose. Patients with no retinopathy or nephropathy at baseline were evaluated in the primary prevention study, while those with established disease were evaluated in the secondary intervention study.",
"   </p>",
"   <p>",
"    The mean A1C values during the nine-year study were 7.2 percent with intensive therapy as opposed to 9.1 percent with conventional therapy; the respective mean blood glucose concentrations were 155",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 235",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (12.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The DCCT provided conclusive evidence that strict glycemic control can both delay the onset of microvascular complications (primary prevention) and slow the rate of progression of already present complications (secondary intervention).",
"   </p>",
"   <p>",
"    Following completion of the DCCT in 1993, the conventional treatment group was offered intensive treatment, and 93 percent of DCCT participants (n = 1394) agreed to participate in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/8\">",
"     8",
"    </a>",
"    ]. Eleven years of follow-up were concluded in February 2005. Differences in A1C levels between the intensive and conventional treatment groups at the end of the DCCT trial (7.4 and 9.1 percent, respectively) narrowed at the end of the 11 year follow-up EDIC (7.9 and 7.8 percent, respectively).",
"   </p>",
"   <p>",
"    The individual microvascular endpoints of the",
"    <span class=\"nowrap\">",
"     DCCT/EDIC",
"    </span>",
"    are discussed immediately below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy has been chosen as the major end-point in many of the prospective diabetes trials because it is the most common microvascular complication and is relatively easy to quantify and follow. Standard retinal photographs are taken and scored, based upon the number of microaneurysms, hemorrhages, exudates, and other abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DCCT demonstrated a substantial benefit of intensive insulin therapy in the primary prevention of diabetic retinopathy: at nine years, the incidence of new retinopathy was 12 percent in the intensive therapy group versus 54 percent in the conventional therapy group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/5\">",
"     5",
"    </a>",
"    ]. There was a continuous relation between the degree of glycemic control and the incidence of retinopathy (the only complication for which such data were reported): the rate of progression increased from one per 100 patient-years at a mean A1C value of 5.5 percent up to 9.5 per 100 patient-years at a mean A1C value of 10.5 percent; progressive retinopathy was uncommon at A1C values below 7 percent (",
"    <a class=\"graphic graphic_figure graphicRef82664 \" href=\"UTD.htm?42/55/43901\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Established retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its efficacy in primary prevention, intensive insulin therapy also slows the rate of progression of mild to moderate retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/11\">",
"     11",
"    </a>",
"    ]. However, during the first two years of intensive therapy, the DCCT found that retinopathy may worsen (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"UTD.htm?28/32/29197\">",
"     figure 2",
"    </a>",
"    ), most commonly in association with an increased number of soft exudates (due to retinal infarcts in the superficial layers) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This probably represents the closure of small retinal blood vessels that were narrowed but patent. Correction of hyperglycemia lowers the plasma volume, which can put marginal vessels at risk. Increased availability of insulin-like growth factor-1 also may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30422?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of diabetic retinopathy\", section on 'Growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This early worsening of retinopathy in the DCCT was transient, largely resolving after 18 to 24 months, and there was clear evidence of benefit from intensive therapy when patients with very mild to moderate nonproliferative retinopathy were followed for nine years (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"UTD.htm?28/32/29197\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/11\">",
"     11",
"    </a>",
"    ]. The incidence of worsening retinopathy in intensively treated patients was higher than in those receiving conventional therapy at one year (7.4 versus 3 percent) but much lower at nine years (25 versus 53 percent).",
"   </p>",
"   <p>",
"    At the end of the DCCT, the conventional treatment group was taught intensive therapy, and the diabetes care of all of the participants was returned to their own health care providers. During the subsequent observational follow-up of the DCCT cohort, in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the difference in the median A1C values between the original intensive and conventional therapy groups (7.2 and 9.1 percent, respectively) narrowed during follow-up (8.1 and 8.2 percent, respectively, by five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, despite the nonsignificant difference in glycemia during EDIC, the reduction in risk of retinopathy associated with intensive insulin therapy persisted for as long as 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Patients who received intensive insulin therapy during the DCCT had a lower incidence of progression of retinopathy (increase of three or more steps from baseline) during the EDIC follow-up period than those who had received conventional therapy during the DCCT (risk reduction 53 percent, 95% CI 43 to 61 percent). Thus, intensive insulin therapy for 6.5 years during the DCCT reduced the risk of retinopathy over at least the next 10 years compared with conventional therapy, despite an absence of a difference in A1C values during the post-DCCT trial period. This phenomenon has been called \"metabolic memory.\"",
"   </p>",
"   <p>",
"    Strict glycemic control is of little or no benefit in advanced retinopathy. This has been best demonstrated in patients who have undergone pancreas transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In one study, for example, 22 transplanted patients (most of whom had advanced nephropathy) were compared with 16 nontransplanted patients with similar disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/18\">",
"     18",
"    </a>",
"    ]. Despite the attainment and maintenance of normoglycemia in the transplant group, there was no difference between the groups in the rates of progression of retinopathy or visual loss at two years. There was some suggestion of less deterioration at three years in the transplanted patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic nephropathy is the most common cause of renal failure in developed countries, although the proportion of patients with type 1 diabetes who progress to end-stage renal disease is declining [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/20\">",
"     20",
"    </a>",
"    ]. Following a cohort of 20,000 individuals diagnosed with type 1 diabetes before the age of 20 years, a Finnish study reported a prevalence of end-stage renal disease of 2.2 percent at 20 years and 7.7 percent at 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/21\">",
"     21",
"    </a>",
"    ]. These prevalence rates are significantly lower than previous estimates of 30 to 40 percent and likely reflect, at least in part, the impact of improved glycemic management.",
"   </p>",
"   <p>",
"    The following discussion will review the evidence related to glycemic control for primary prevention, established microalbuminuria, and established macroalbuminuria in patients with type 1 diabetes. The role of antihypertensive drugs for renal protection, particularly ACE inhibitors or angiotensin II receptor blockers, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DCCT included 1365 patients with normal albumin excretion at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/5\">",
"     5",
"    </a>",
"    ]. At follow-up of up to nine years (mean 6.5 years), intensive therapy led to a significant reduction in the incidence of new onset microalbuminuria (16.4 versus 23.9 percent, adjusted risk reduction 39 percent) (",
"    <a class=\"graphic graphic_figure graphicRef73143 \" href=\"UTD.htm?18/21/18781\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/22\">",
"     22",
"    </a>",
"    ]. There was also a significant reduction in new onset macroalbuminuria in the entire study population (3.2 versus 7.2 percent, adjusted risk reduction 51 percent).",
"   </p>",
"   <p>",
"    Similar to the case with retinopathy, metabolic memory applies to the primary prevention of nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. Significant persistent benefits were noted in those who had received intensive therapy compared with those who received conventional therapy during the DCCT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After eight years of follow-up in EDIC, patients originally assigned to intensive glycemic control were significantly less likely to develop new microalbuminuria (7 versus 16 percent), new clinical albuminuria, also called macroalbuminuria, (1.4 versus 9 percent), and hypertension (30 versus 40 percent).",
"     </li>",
"     <li>",
"      After 16 years of follow-up in EDIC (22 years since in the start of the DCCT trial), patients originally assigned to intensive glycemic control were significantly less likely to develop impaired renal function, defined as an estimated glomerular filtration rate less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (3.9 versus 7.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, previous intensive treatment with near-normal glycemia during the DCCT had an extended benefit in delaying the onset and progression of diabetic nephropathy.",
"   </p>",
"   <p>",
"    A similar benefit of intensive therapy was noted in a smaller prospective study of 102 patients who were followed for an average of 7.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/7\">",
"     7",
"    </a>",
"    ]. Most of the patients had no albuminuria at baseline. The A1C value was reduced from 9.5 to 7.1 percent in the intensively treated group (most of whom took at least three insulin injections daily) versus 9.4 to 8.5 percent with standard therapy. Progression from no protein excretion to microalbuminuria or overt proteinuria occurred in 3 and 24 percent in the intensive and standard treatment groups, respectively. Overt nephropathy with a subnormal glomerular filtration rate developed in six patients in the standard therapy group but in no patient achieving strict glycemic control.",
"   </p>",
"   <p>",
"    The observations that combined renal and pancreas transplantation (the latter to restore normoglycemia) can prevent and that intensive insulin therapy can delay recurrent diabetic nephropathy in renal allografts is further evidence of the protective effect of meticulous glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link&amp;anchor=H13#H13\">",
"     \"Renal transplantation in diabetic nephropathy\", section on 'Recurrent diabetic nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intensive insulin therapy may act in part by reversing the early glomerular hyperfiltration and hypertrophy that are thought to be important risk factors for glomerular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Established microalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive insulin therapy is also effective at a somewhat later stage, after microalbuminuria has developed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/13,22,27\">",
"     13,22,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link&amp;anchor=H17#H17\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Glucose control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There were only 73 patients in DCCT with microalbuminuria at baseline and too few of these patients progressed to macroalbuminuria to demonstrate significant benefit from intensive insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the magnitude of the benefit from intensive insulin therapy was similar to that seen in the much larger population of patients with normoalbuminuria described in the preceding section.",
"   </p>",
"   <p>",
"    A meta-analysis of 226 patients in seven earlier trials of type 1 diabetes also found benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/13\">",
"     13",
"    </a>",
"    ]. Among patients with either no albuminuria or microalbuminuria, the odds ratio for increasing albumin excretion was 0.34 in patients receiving intensive therapy compared with those receiving conventional therapy.",
"   </p>",
"   <p>",
"    In addition to preventing progression, maintenance of relative normoglycemia often diminishes the degree of protein excretion, although one to two years are usually required for this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Established macroalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the benefit of aggressive therapy in patients with microalbuminuria, it has been suggested that strict glycemic control with intensive insulin therapy may not slow the rate of progressive renal injury once overt dipstick-positive proteinuria (equivalent to albuminuria &gt;300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    called macroalbuminuria or overt proteinuria) has developed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, results from pancreatic transplant recipients in whom true euglycemia is restored suggest that this may not be correct at prolonged follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In eight patients with type 1 diabetes who had pancreatic transplantation (three patients had normal albumin excretion, three had microalbuminuria, and two had overt proteinuria), transplantation stabilized but did not improve glomerular structure at five year follow-up; however, benefits were observed at 10 years (",
"    <a class=\"graphic graphic_figure graphicRef67651 \" href=\"UTD.htm?29/43/30384\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of diabetic nephropathy\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of restored normoglycemia, which can currently be achieved only with pancreas or islet transplantation, the apparent lack of substantial benefit in overt diabetic nephropathy from strict glycemic control alone suggests that other factors (such as intraglomerular hypertension and glomerular hypertrophy) may contribute to the progressive glomerular injury. At this late stage, there is often marked glomerulosclerosis. Only antihypertensive therapy (preferably with an angiotensin converting enzyme inhibitor) and perhaps dietary protein restriction have been shown to slow the rate of progressive disease or reverse established lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of diabetic nephropathy\", section on 'Role of other factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first evidence that improved glycemic control has a beneficial effect on painful diabetic neuropathy came from a report of nine patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/32\">",
"     32",
"    </a>",
"    ]. Initiation of intensive therapy led to symptomatic improvement in all patients in association with increases in vibration sense and motor (but not sensory) nerve conduction velocity. This study was uncontrolled and its findings of uncertain importance since spontaneous improvement in neuropathic symptoms can occur, particularly if the symptoms were preceded by deterioration in metabolic control [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, subsequent prospective studies have confirmed the ability of improved glycemic control to prevent or slow the progression of neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/7,34,35\">",
"     7,34,35",
"    </a>",
"    ]. In the DCCT, for example, the following benefits were noted (",
"    <a class=\"graphic graphic_figure graphicRef70914 graphicRef50952 \" href=\"UTD.htm?12/40/12943\">",
"     figure 5A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of confirmed clinical neuropathy (defined as findings from the history and physical examination that were confirmed by neurologic testing) was reduced with intensive insulin therapy by 64 percent (5 versus 13 percent).",
"     </li>",
"     <li>",
"      Intensive insulin therapy also reduced the incidence of abnormal nerve conduction by 44 percent (26 versus 46 percent) and of autonomic dysfunction by 53 percent (4 versus 9 percent).",
"     </li>",
"     <li>",
"      In patients with possible or definite mild neuropathy at baseline, intensive insulin therapy was associated with an improvement in nerve conduction velocity (",
"      <a class=\"graphic graphic_figure graphicRef70945 \" href=\"UTD.htm?4/16/4367\">",
"       figure 6",
"      </a>",
"      ). Whether this will translate into a reduction in the incidence of progressive symptomatic neuropathy is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations indicate that an intensive insulin regimen to improve glycemic control delays or prevents clinical and physiological evidence of diabetic neuropathy. The Oslo study suggested that there was a graded effect of hyperglycemia on disease progression, as each 1 percent rise in A1C values was associated with a 1.3",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    slowing of nerve conduction at eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other potentially modifiable risk factors appear to be associated with the risk of diabetic neuropathy, including hypertriglyceridemia, obesity, smoking, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/36\">",
"     36",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MACROVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DCCT found a nonsignificant trend toward fewer cardiovascular events with intensive therapy (3.2 versus 5.4 percent, p = 0.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/37\">",
"     37",
"    </a>",
"    ]. The intensive insulin therapy group also had lower serum LDL cholesterol concentrations but, due to the increase in insulin administration, some weight gain.",
"   </p>",
"   <p>",
"    Following completion of the DCCT in 1993, the conventional treatment group was offered intensive treatment and 93 percent of DCCT participants (n = 1394) agreed to participate in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/8\">",
"     8",
"    </a>",
"    ]. Differences in A1C levels between the intensive and conventional treatment groups at the end of the DCCT trial (7.4 and 9.1 percent, respectively) narrowed at the end of the 11 year follow-up EDIC (7.9 and 7.8 percent, respectively). The mean duration of intensive therapy during the DCCT period had been 6.5 years.",
"   </p>",
"   <p>",
"    Cardiovascular outcomes for the EDIC were defined as the occurrence of non-fatal MI, stroke, cardiovascular death, documented angina, or coronary revascularization. The analysis of cardiovascular events according to original DCCT treatment assignment was predetermined to conclude when 50 patients in the original conventional treatment group had experienced a cardiovascular event.",
"   </p>",
"   <p>",
"    During the entire follow-up period (mean 17 years), 46 events had occurred in 31 patients from the DCCT intensive therapy group, compared with 98 events in 52 patients from the conventional therapy group (0.38 versus 0.80 events per 100 patient-years). This represented a 42 percent decrease in any cardiovascular event (95% CI 9 to 63 percent); there was also a 57 percent reduction in a serious cardiovascular event (non-fatal MI, stroke, or CVD death; 95% CI 12 to 79 percent) comparing the original DCCT intensive therapy with the DCCT conventional treatment group.",
"   </p>",
"   <p>",
"    The difference in levels of glycemic control between the treatment groups, as measured by the A1C during the DCCT, accounted for most of the difference in cardiovascular events between the two groups. Microalbuminuria and albuminuria were also independently associated with cardiovascular outcome, but differences in outcome between the two treatment groups remained after correction for these renal factors.",
"   </p>",
"   <p>",
"    These results indicate that a sustained period of glycemic control (6.5 years in the DCCT study) has lasting benefit in reducing cardiovascular morbidity and mortality in type 1 diabetes.",
"   </p>",
"   <p>",
"    The results are supported by similar findings from a cohort study of 879 individuals with type 1 diabetes followed for 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/38\">",
"     38",
"    </a>",
"    ]. In this study, individuals in the highest quartile of A1C (&ge;12 percent) had increased all-cause (relative risk [RR] 2.4, 95% CI 1.5-3.8) and cardiovascular (RR 3.3, 95% CI 1.8-6.1) mortality compared with individuals in the lowest quartile (&le;9.4 percent).",
"   </p>",
"   <p>",
"    Mechanisms postulated to account for this effect include decreased exposure to advanced glycosylation end products, or a secondary consequence of decreased renal disease and autonomic neuropathy that have been implicated in cardiovascular disease risk. An earlier report from the EDIC study showed that progression of carotid intima-media thickness, a measure of atherosclerosis, was significantly less in those who had received intensive therapy during the DCCT compared with those who had received conventional therapy (progression of intima-media thickness of the common carotid artery 0.032 versus 0.046 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GLYCEMIC TARGETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above findings provide conclusive evidence that strict glycemic control, if achieved before irreversible end-organ damage has occurred, reduces the incidence of microvascular disease, neurologic dysfunction, and cardiovascular disease in patients with type 1 diabetes.",
"   </p>",
"   <p>",
"    Additional data from the DCCT support the importance of beginning intensive therapy as early as possible after the diagnosis of type 1 diabetes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of 303 patients in the primary prevention cohort (one to five years of duration) who had residual beta-cell function (as evidenced by a serum C-peptide concentration of 0.20 to 0.50",
"      <span class=\"nowrap\">",
"       pmol/mL",
"      </span>",
"      after ingestion of a standardized meal) and were randomly assigned to intensive or conventional insulin therapy, those receiving intensive therapy had lower A1C values, were less likely to lose residual beta-cell function (risk reduction 57 percent), and had a 50 percent reduction in the risk for progression of retinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/40\">",
"       40",
"      </a>",
"      ]. They also had a lower risk for severe hypoglycemia compared with those who received intensive therapy but did not have residual beta-cell function.",
"     </li>",
"     <li>",
"      Long-term observational data from the",
"      <span class=\"nowrap\">",
"       DCCT/EDIC",
"      </span>",
"      study showed that patients with type 1 diabetes duration of 30 years, who were initially assigned to intensive versus conventional therapy, had the lowest cumulative incidences of proliferative retinopathy (21 versus 50 percent), nephropathy (9 versus 25 percent), and cardiovascular disease (9 versus 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, intensive insulin therapy should be attempted in all appropriate patients with type 1 diabetes as early in the course of disease as is safely feasible. Both patient and clinician education and support are required to perform this task safely. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hypoglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    From a renal viewpoint, this regimen has demonstrated to be beneficial in all patients except those with overt proteinuria in whom strict blood pressure control with an ACE inhibitor appears to be more important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H26#H26\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mean A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal level of glycemic control is uncertain. As noted above, the risk of retinopathy in type 1 diabetes does not plateau at an A1C value of 7 percent (using the DCCT assay or its equivalent). There is further improvement at A1C values between 5.5 and 7 percent (",
"    <a class=\"graphic graphic_figure graphicRef82664 \" href=\"UTD.htm?42/55/43901\">",
"     figure 1",
"    </a>",
"    ), but at the cost of an increased risk of hypoglycemia (",
"    <a class=\"graphic graphic_figure graphicRef59452 \" href=\"UTD.htm?5/41/5789\">",
"     figure 7",
"    </a>",
"    ). A similar relationship applies with nephropathy.",
"   </p>",
"   <p>",
"    In general, we aim for an A1C value of 7 percent or lower in patients in whom the benefits outweigh the risks. Specific glycemic targets should be set for individual patients, weighing benefits related to life-expectancy and existing complications against the risk of hypoglycemia. In general, A1C goals are set higher for children and adolescents, especially in children with frequent hypoglycemia or hypoglycemia unawareness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing the intensity of glycemic control to achieve A1C &lt;7 percent is indicated during pregnancy in type 1 and type 2 diabetic women, since the A1C level in nondiabetic women falls during pregnancy and the demonstrated benefits to the fetus and neonate drive the therapeutic goals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=see_link\">",
"     \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Glycemic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of fluctuations in glucose levels, as measured within or between days, on the risk of developing diabetic complications is uncertain. This has theoretical clinical implications, as free radicals have been implicated in endothelial damage and the formation of atherosclerotic plaques. One may therefore hypothesize that control of daily blood glucose fluctuations, in addition to management of chronic hyperglycemia (as measured by A1C) in diabetic patients, could be important in protection against micro- and macrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of data from the DCCT demonstrated that while retinopathy correlated directly with average glucose control, as measured by the A1C, fluctuations of glucose within the day (glucose variability) did not impact the development of retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/43\">",
"     43",
"    </a>",
"    ]. Additional data are needed before glycemic variability can be established as an independent predictor of complication risk. In the interim, titrating insulin to achieve an optimal A1C value (&le;7.0 percent) should be the primary goal, as glycemic variability should improve with intensive insulin titration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific glycemic targets should be set for individual patients, weighing benefits related to life-expectancy and existing complications against the risk of hypoglycemia. In the DCCT, hypoglycemia was continuously, but inversely, related to glycemic control, ranging from approximately 105 to 25 episodes per 100 patient-years at mean A1C values of 5.5 and 10.5 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef59452 \" href=\"UTD.htm?5/41/5789\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11817/abstract/5\">",
"     5",
"    </a>",
"    ]. Hypoglycemia is more likely to occur in diabetic patients if they also develop impaired release of the protective counterregulatory hormones glucagon, which is common after 10 years diabetes duration, and epinephrine, a manifestation of autonomic neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       \"Patient information: Using insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DCCT demonstrated that intensive therapy aimed at lower levels of glycemia results in decreased rates of retinopathy, nephropathy, and neuropathy in type 1 diabetes patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microvascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the EDIC follow-up study to the DCCT, intensive insulin therapy for 6.5 years during the DCCT reduced the risk of retinopathy and nephropathy over at least the next 10 years compared with conventional therapy, despite an absence of a difference in A1C values during the post-DCCT trial period. This phenomenon has been called \"metabolic memory.\" (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Retinopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the EDIC follow-up study to the DCCT, intensive insulin therapy in patients with type 1 diabetes decreased fatal and nonfatal cardiovascular events. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Macrovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Target A1C levels in patients with type 1 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. A reasonable goal of therapy might be an A1C value of &le;7.0 percent for most patients (using an assay in which the upper limit of normal is 6.0 percent).",
"      <br/>",
"      <br/>",
"      Glycemic targets are generally set somewhat higher for children, adolescents, and older patients with comorbidities or a limited life expectancy and little likelihood of benefit from intensive therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glycemic targets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/1\">",
"      Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988; 318:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/2\">",
"      Molitch ME, Steffes MW, Cleary PA, Nathan DM. Baseline analysis of renal function in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group [corrected]. Kidney Int 1993; 43:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/3\">",
"      Dahl-J&oslash;rgensen K, Bj&oslash;ro T, Kierulf P, et al. Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus. Kidney Int 1992; 41:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/4\">",
"      Barzilay J, Warram JH, Bak M, et al. Predisposition to hypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int 1992; 41:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/5\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/6\">",
"      The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/7\">",
"      Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/8\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/9\">",
"      Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/10\">",
"      Mauer SM, Goetz FC, McHugh LE, et al. Long-term study of normal kidneys transplanted into patients with type I diabetes. Diabetes 1989; 38:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/11\">",
"      Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/12\">",
"      Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/13\">",
"      Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/14\">",
"      Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/15\">",
"      Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/16\">",
"      Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/17\">",
"      White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/18\">",
"      Ramsay RC, Goetz FC, Sutherland DE, et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988; 318:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/19\">",
"      Wang Q, Klein R, Moss SE, et al. The influence of combined kidney-pancreas transplantation on the progression of diabetic retinopathy. A case series. Ophthalmology 1994; 101:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/20\">",
"      Daneman D. Type 1 diabetes. Lancet 2006; 367:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/21\">",
"      Finne P, Reunanen A, Stenman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/22\">",
"      Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/23\">",
"      Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/24\">",
"      DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/25\">",
"      Tuttle KR, Bruton JL, Perusek MC, et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/26\">",
"      Tuttle KR, Bruton JL. Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 1992; 42:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/27\">",
"      Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/28\">",
"      Bending JJ, Viberti GC, Watkins PJ, Keen H. Intermittent clinical proteinuria and renal function in diabetes: evolution and the effect of glycaemic control. Br Med J (Clin Res Ed) 1986; 292:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/29\">",
"      Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992; 20:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/30\">",
"      Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 1993; 342:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/31\">",
"      Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/32\">",
"      Boulton AJ, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982; 5:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/33\">",
"      Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care 1988; 11:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/34\">",
"      Amthor KF, Dahl-J&oslash;rgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/35\">",
"      The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995; 122:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/36\">",
"      Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/37\">",
"      Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/38\">",
"      Shankar A, Klein R, Klein BE, Moss SE. Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 2007; 166:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/39\">",
"      Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/40\">",
"      Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998; 128:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/41\">",
"      Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/42\">",
"      Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006; 295:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11817/abstract/43\">",
"      Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29:1486.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1751 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11817=[""].join("\n");
var outline_f11_34_11817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Retinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Established retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Established microalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Established macroalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MACROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GLYCEMIC TARGETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mean A1C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Glycemic variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1751|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/42/32430\" title=\"algorithm 1\">",
"      Hyperglycemic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1751|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/55/43901\" title=\"figure 1\">",
"      Retinopathy and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/32/29197\" title=\"figure 2\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/21/18781\" title=\"figure 3\">",
"      Nephropathy and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/43/30384\" title=\"figure 4\">",
"      Reversal of diabetic nephropathy after pancreas TPL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/56/39821\" title=\"figure 5A\">",
"      Neuropathy and glycemic control I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/8/3214\" title=\"figure 5B\">",
"      Neuropathy and glycemic control II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/16/4367\" title=\"figure 6\">",
"      Established neuropathy glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/41/5789\" title=\"figure 7\">",
"      Hypoglycemia and HbA1c",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30422?source=related_link\">",
"      Pathogenesis of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39207?source=related_link\">",
"      Protein kinase C and the vascular complications of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=related_link\">",
"      Renal transplantation in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11818="Clinical manifestations, pathophysiology, and diagnosis of atrioventricular (AV) canal defects";
var content_f11_34_11818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathophysiology, and diagnosis of atrioventricular (AV) canal defects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11818/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11818/contributors\">",
"     Craig E Fleishman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11818/contributors\">",
"     Aykut Tugertimur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11818/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11818/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11818/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/34/11818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/34/11818/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/34/11818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6370563\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) canal defects are a group of congenital cardiac defects involving the AV septum and AV valves (ie, mitral and tricuspid valves). They are also referred to as AV septal defects, endocardial cushion defects, or persistent AV ostium. Combinations of these anatomic abnormalities result in complete (both atrial and ventricular septal defects) and partial (only atrial septal defect) forms that are manifested in varying clinical presentations.",
"   </p>",
"   <p>",
"    The anatomy, pathophysiology, clinical features, and diagnosis of AV canal defects will be reviewed here. The management and outcome of patients with AV canal defects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/48?source=see_link\">",
"     \"Management and outcome of atrioventricular (AV) canal defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370570\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) canal defects account for about 4 to 5 percent of congenital heart defects with a reported prevalence of 0.3 to 0.4 per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. AV canal defects in fetuses accounted for a larger proportion of detected congenital heart disease (CHD) approaching 18 percent of CHD cases based on data from large fetal echocardiographic series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The male-to-female distribution of AV canal defect is approximately equal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/5\">",
"     5",
"    </a>",
"    ], and complete AV canal defects with both atrial and ventricular septal defects occur in half of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a strong association between AV canal defects and trisomy 21 (also referred to as Down syndrome) with a 40 to 50 percent risk of Down syndrome in fetuses in whom an AV canal defect is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/6\">",
"     6",
"    </a>",
"    ]. Nonsyndromic AV canal defects appear to be associated with maternal diabetes and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21118024\">",
"     'Trisomy 21'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450999423\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450999431\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) canal defects encompass a broad range of AV septal defects and abnormalities of the AV valves. An initial classification separates the different types of AV canal defects based on anatomical features (eg, complete versus partial form) and their impact on physiology. In addition, variations of complete AV canal defects are categorized by AV valve morphology (Rastelli classification) and relative ventricular size. These classifications are used to guide surgical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450999438\">",
"    <span class=\"h2\">",
"     Complete, partial, intermediate, and transitional forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV canal defects are initially divided between complete (which contain",
"    <strong>",
"     both",
"    </strong>",
"    atrial and ventricular septal defects) and partial defects (which have an atrial septal but",
"    <strong>",
"     no",
"    </strong>",
"    ventricular septal defect). Two other forms are subtypes of complete AV canal defects and include transitional (physiologically similar to the partial subtype) and intermediate (physiologically similar to the common subtype) defects (",
"    <a class=\"graphic graphic_figure graphicRef86346 \" href=\"UTD.htm?25/5/25686\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete AV canal defect is a result of complete failure of fusion between the superior and inferior endocardial cushions. It is characterized by a primum atrial septal defect (ASD) that is contiguous with a posterior (or inlet) ventricular septal defect (VSD), and a common AV valve.",
"     </li>",
"     <li>",
"      Partial AV canal defect is due to incomplete fusion of the superior and inferior endocardial cushions and consists of a primum ASD, and a single AV valve annulus with two separate valve orifices. Due to abnormal fusion of the left tubercle of the superior and inferior cushions, the anterior leaflet of the mitral valve typically is cleft.",
"     </li>",
"     <li>",
"      Transitional AV canal defect is anatomically a subtype of complete AV canal defect as it consists of a large primum defect, cleft mitral valve, and inlet ventricular septal defect. However, dense chordal attachments to the ventricular septum lead to small insignificant ventricular shunting and delineation of distinct left and right AV valve orifices resulting in a defect that is similar to the physiology of a partial AV canal defect.",
"     </li>",
"     <li>",
"      Intermediate AV canal defect is a rare subtype of complete AV canal defect, in which a bridging tongue of tissue divides the common AV valve into two distinct orifices. This defect is similar to a complete AV canal defect and usually has both a large primum atrial and inlet ventricular septal defects. Due to the natural division of the common AV valve into left and right AV valve components by the tongue of tissue, surgical division is not required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450999445\">",
"    <span class=\"h2\">",
"     Rastelli classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification system initially developed and revised by Rastelli and others is used to describe the anatomy of the superior bridging leaflet of the common AV valve in patients with a complete AV defect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The common AV valve is composed of five leaflets: left superior and inferior bridging leaflets, a left lateral leaflet, right anterior leaflet, and right lateral leaflet. The superior bridging leaflet is more variable in its size and attachments than the other four leaflets. Initially, the Rastelli classification was important in describing morphological details of the AV valve that was used for surgical repair. However, over time, the clinical and surgical significance of the Rastelli classification has become less important (",
"    <a class=\"graphic graphic_figure graphicRef86329 \" href=\"UTD.htm?28/51/29488\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rastelli type A defects are the most common form and are frequently found in patients who have Down syndrome. In this form, the superior bridging leaflet is committed to the left ventricle with chordal attachments to the crest of the ventricular septum. It shares a commissure with the anterior tricuspid leaflet at the ventricular septum. Interventricular shunting may occur between the anterior and posterior bridging leaflets and underneath the anterior leaflet in the interchordal spaces.",
"     </li>",
"     <li>",
"      Rastelli type B is the least common form, in which the superior bridging leaflet extends into the right ventricle with a corresponding decrease in size of the anterior tricuspid leaflet and with chordal attachments into the body of the right ventricle. Because of the lack of chordal insertions to the septum, interventricular shunting occurs under the superior bridging leaflet.",
"     </li>",
"     <li>",
"      Rastelli type C is frequently found in combination with other cardiac defects, such as tetralogy of Fallot, transposition of the great arteries, and heterotaxy syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. In this form, the superior bridging leaflet is even larger and has no chordal attachment to the interventricular septum, referred to as &ldquo;free floating&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/10-12\">",
"       10-12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450999452\">",
"    <span class=\"h2\">",
"     Balanced/unbalanced classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete AV canal defects can also be classified based on the relative sizes of the ventricles. In a balanced complete AV canal defect, the ventricles are relatively equal in size and are amendable to two-ventricular surgical correction. In the unbalanced form, there is hypoplasia of either the right or left ventricle. In most unbalanced cases, the right ventricle is the dominant ventricle. If there is significant hypoplasia of either ventricle, complete two-ventricle surgical repair may not be possible, and palliative procedures need to be considered. Echocardiographic indices are used to determine the possibility of successful two-ventricle repair of unbalanced AV canal defects versus the need to pursue a single ventricle palliative approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/48?source=see_link&amp;anchor=H8314469#H8314469\">",
"     \"Management and outcome of atrioventricular (AV) canal defects\", section on 'Single ventricle palliation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370577\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY AND ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21118084\">",
"    <span class=\"h2\">",
"     Normal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal development, the primitive atrioventricular (AV) canal connects the atria to the ventricles. At four to five weeks of gestation, the superior and inferior endocardial cushions of the common AV canal fuse and contribute to the formation of the AV valves (ie, mitral and tricuspid valves) and the AV septum (",
"    <a class=\"graphic graphic_figure graphicRef86165 \" href=\"UTD.htm?19/29/19923\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21118091\">",
"    <span class=\"h2\">",
"     Anatomy of AV canal defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of these cushions to fuse correctly results in a broad range of AV septal defects and abnormalities of the AV valves (",
"    <a class=\"graphic graphic_figure graphicRef86338 \" href=\"UTD.htm?39/23/40312\">",
"     figure 4",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"    In patients with AV canal defects, the AV valve(s) is displaced apically and the inlet portion of the ventricular septum appears &ldquo;scooped out,&rdquo; resulting in a shorter distance from the crux to the apex of the heart than from apex to the aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete failure of fusion between the superior and inferior endocardial cushions results in both large atrial (primum atrial septal defect) and ventricular septal defects (due to a deficiency of the inlet portion of the interventricular septum), and a single common AV valve.",
"     </li>",
"     <li>",
"      Incomplete or partial lack of fusion between the superior and inferior cushions results in a partial AV canal defect with a primum atrial septal defect, a common valvular annulus with two separate AV valve orifices, and a cleft in the anterior mitral leaflet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779748176\">",
"    <span class=\"h3\">",
"     AV valve abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both complete and partial AV canal defects, the AV valve(s) is usually abnormal, resulting in regurgitation. Over time, the valve leaflets become more thickened, with prolapse of leaflet tissue and worsening regurgitation. Even after repair, the continued presence of AV valve regurgitation is a significant cause of morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779748114\">",
"    <span class=\"h4\">",
"     Complete AV canal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complete AV canal defects have a single AV valve, which is often associated with regurgitation. Regurgitation through the common valve may be from left ventricle to left atrium or right ventricle to right atrium. It can exacerbate volume overload and contribute to heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983938\">",
"    <span class=\"h4\">",
"     Partial AV canal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitral valve in partial AV canal defects is almost always abnormal. There is usually a cleft of the anterior leaflet, which is often associated with mitral regurgitation. Regurgitation is most common from the left ventricle to left atrium through the cleft in the anterior mitral valve leaflet. However, regurgitation can also occur from the left ventricle to right atrium through the AV septum, resulting in a &ldquo;left ventricle to right atrium shunt,&rdquo; and right atrial and right ventricular volume overload.",
"   </p>",
"   <p>",
"    Double-orifice mitral valve is an uncommon but surgically important abnormality. It is found in approximately 4 to 5 percent of all patients with AV canal defects. The combined effective opening of a double orifice mitral valve is always less than that of a valve with a single orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Double-orifice mitral valve is a risk factor for poor surgical outcome because of significant regurgitation. However, combining the two orifices by incising bridging tissue is not optimal as it also commonly results in significant left AV valve (mitral) regurgitation.",
"   </p>",
"   <p>",
"    A parachute mitral valve is associated with papillary muscle abnormalities. The papillary muscles in AV canal defects are usually abnormal in size and location [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The left ventricular",
"    <strong>",
"    </strong>",
"    (LV) papillary muscles in AV canal defects are typically shifted laterally and closer together compared with their usual location. On occasion, only one LV papillary muscle may be present, resulting in parachute mitral valve deformity. In such a patient, traditional repair with closure of the cleft may result in postoperative mitral valve stenosis or disruption of the mitral valve tensor apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983827\">",
"    <span class=\"h3\">",
"     Left ventricular outflow tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined changes of valve position and septal deficiency increase the distance between the aorta and the apex of the heart, resulting in an elongation of the left ventricular outflow tract (LVOT). This anatomic change is visualized by echocardiography and angiography as a gooseneck deformity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86328 \" href=\"UTD.htm?14/7/14450\">",
"     image 1",
"    </a>",
"    ). Although the LVOT appears elongated and narrow, in most cases, there is no obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    When LVOT obstruction occurs, it typically presents in patients with partial AV canal defect, because the superior bridging leaflet is frequently bound tightly to the septal crest causing the LVOT to be longer and more narrow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86335 \" href=\"UTD.htm?21/12/21700\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential sources of the LVOT obstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accessory papillary muscle extending to the LVOT tract",
"     </li>",
"     <li>",
"      Discrete subaortic membrane",
"     </li>",
"     <li>",
"      Aneurysm of membranous ventricular septum into the outflow region",
"     </li>",
"     <li>",
"      Aortic arch hypoplasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aortic coarctation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8312591\">",
"    <span class=\"h3\">",
"     Associated cardiac defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cardiac defects are frequently found in patients with AV canal defects, such as tetralogy of Fallot (TOF). In particular, commonly associated cardiac lesions in patients with complete AV canal defects include transposition of the great arteries, heterotaxy syndrome, patent ductus arteriosus, coarctation of the aorta, secundum atrial septal defects, absent atrial septum, muscular ventricular septal defects, persistent left superior vena cava, and anomalous pulmonary venous return [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/25\">",
"     25",
"    </a>",
"    ]. Pulmonary and systemic venous abnormalities may also be associated with AV canal defects as a part of the heterotaxy syndrome (a rare condition in which the usual position of the heart and other organs are reversed as mirror images of the normal location [ie, situs inversus]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11984932\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) canal defects are thought to be caused by a disruption of the normal development of the endocardial cushions due to an underlying genetic defect or predisposition. This theory is supported by evidence from animal molecular biology studies and human genetic observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779748217\">",
"    <span class=\"h2\">",
"     Molecular biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from animal studies suggest that the abnormal transformation of epithelial cells to mesenchymal cells during the development of the endocardial cushions leads to AV canal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a mouse model of Down syndrome (trisomy 16 mouse), there is a 100 percent incidence of AV canal defects. In these affected mice, the mesenchymal cell",
"      <strong>",
"      </strong>",
"      density is lower and their migration is slower,",
"      <strong>",
"      </strong>",
"      which results in an elongated endocardial cushion region compared with normal development in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of chick",
"      <strong>",
"      </strong>",
"      embryos have established transforming growth factor beta as a",
"      <strong>",
"      </strong>",
"      mediator in epithelial-mesenchymal cell transformation during endocardial cushion development [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In mice, bone morphogenetic proteins (BMP) appear to be essential to normal epithelial-mesenchymal cell transformation and normal AV canal development [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/29-32\">",
"       29-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21118024\">",
"    <span class=\"h2\">",
"     Trisomy 21",
"    </span>",
"    &nbsp;&mdash;&nbsp;In humans, there is a strong association between AV canal defects and trisomy 21 (also referred to as Down syndrome). Fetuses in whom an AV canal defect is detected have a 40 to 50 percent risk of Down syndrome. Conversely, approximately 40 percent of fetuses with trisomy 21 have an AV canal defect, usually the complete form. In addition, the combination of AV canal defect and tetralogy of Fallot is highly suggestive of Down syndrome, as 75 percent of patients with both defects have Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on molecular mapping of small regions of duplication on chromosome 21, the region at 21q22.1-qter has been designated an AV canal critical region (also referred to as the Down syndrome critical region) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/6\">",
"     6",
"    </a>",
"    ]. This region of the human genome is homologous to that of the trisomy 16 mouse model, in which, as noted above, there is a 100 percent incidence of AV canal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/33\">",
"     33",
"    </a>",
"    ]. Molecular studies of patients with congenital heart disease (CHD) and partial duplications of chromosome 21 have identified a candidate gene for Down syndrome and CHD that encodes a cell adhesion molecule that is expressed in the heart during cardiac development [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening for Down syndrome is recommended when AV canal defects are diagnosed by fetal echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Heart disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21118053\">",
"    <span class=\"h2\">",
"     Heterotaxy",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV canal defects are also prominent components of heterotaxy syndrome occurring in two-thirds of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The complete AV canal defect with double outlet right ventricle combination is common in patients with heterotaxy syndrome, especially the asplenia form. Heterotaxy syndrome is a rare condition in which the usual position of the heart and other organs are reversed as mirror images of the normal location (ie, situs inversus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370661\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1062508\">",
"    <span class=\"h2\">",
"     Complete AV canal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete atrioventricular (AV) canal defects result in increased pulmonary blood flow because of left-to-right shunting at the atrial and ventricular levels (",
"    <a class=\"graphic graphic_figure graphicRef86346 \" href=\"UTD.htm?25/5/25686\">",
"     figure 1",
"    </a>",
"    ). As a result, excessive pulmonary blood flow in patients with unrepaired defects typically leads to heart failure and, eventually, elevated pulmonary vascular resistance. Almost all uncorrected patients with complete AV canal defect will develop heart failure symptoms (eg, failure to thrive and respiratory) prior to one year of age. Unrestrictive interventricular communication and significant AV valve regurgitation eventually lead to pulmonary artery hypertension. If the patient does not develop heart failure symptoms early on, premature development of pulmonary vascular obstructive disease (PVOD) should be suspected. (See",
"    <a class=\"local\" href=\"#H6370705\">",
"     'Complete AV canal defect'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370668\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension and Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is rare to have irreversible PVOD in patients younger than one year of age; however, fixed and elevated pulmonary vascular resistance has been demonstrated in 11 percent of infants less than one year of age with Down syndrome and AV canal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/38\">",
"     38",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Because patients with Down syndrome have other potential contributors to pulmonary hypertension, it is likely (although uncertain) that these factors may contribute to the accelerated progression of pulmonary vascular disease rather than be solely attributable to cardiac disease. Other noncardiac factors associated with pulmonary hypertension in patients with Down syndrome include chronic upper airway disease, tonsillar and adenoid hypertrophy with associated obstructive sleep apnea (OSA), and inadequate alveolarization of the terminal bronchioles (which leads to a decreased surface area of the vascular bed) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/39\">",
"     39",
"    </a>",
"    ]. Supportive evidence that noncardiac factors play a role in the development of pulmonary hypertension includes a study that failed to demonstrate histologic differences in pulmonary vascular changes between patients with Down syndrome and AV canal defect, and children without Down syndrome who also had an AV canal defect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H5936278#H5936278\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Pulmonary disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370675\">",
"    <span class=\"h2\">",
"     Partial AV canal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial AV canal defects have left-to-right shunting at the level of the primum atrial septal defect (",
"    <a class=\"graphic graphic_figure graphicRef86346 \" href=\"UTD.htm?25/5/25686\">",
"     figure 1",
"    </a>",
"    ). This causes volume overload of the right atrium and ventricle, and pulmonary overcirculation, but the pulmonary artery pressures are usually normal to mildly elevated. As a result, symptoms may remain minimal until adulthood.",
"   </p>",
"   <p>",
"    If there is significant mitral regurgitation, symptoms of heart failure may occur because of increased atrial shunting. In contrast, symptoms of pulmonary edema may be absent even in the presence of left atrial hypertension due to mitral valve regurgitation, because of decompression across the atrial septal defect. Patients with partial AV canal defect and severe mitral regurgitation may also present with atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8312681\">",
"    <span class=\"h2\">",
"     Transitional AV canal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventricular shunting in transitional AV canal defects is usually minimal due to a small and restrictive ventricular septal defect. The pathophysiology and clinical presentation of transitional AV canal defects are similar to those of partial AV canal defects. These patients may have a left ventricle to right atrium shunt and, rarely, significant AV regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370682\">",
"    <span class=\"h2\">",
"     AV valve regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with complete and partial AV canal defects, the AV valves are usually abnormal and incompetent resulting in regurgitation. (See",
"    <a class=\"local\" href=\"#H21118091\">",
"     'Anatomy of AV canal defects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In complete defects, regurgitation through the common valve may be from left ventricle to left atrium or right ventricle to right atrium.",
"     </li>",
"     <li>",
"      In partial defects, most of the regurgitation is from left ventricle to left atrium through the cleft in the anterior mitral valve leaflet. However, regurgitation can also occur between the left ventricle and right atrium through the AV septum, resulting in the typical &ldquo;left ventricle to right atrium shunt&rdquo; and right atrial and ventricular volume overload.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370689\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370698\">",
"    <span class=\"h2\">",
"     Fetal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in ultrasound technology have enabled accurate diagnosis of atrioventricular (AV) canal defects as early as the first trimester (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86330 \" href=\"UTD.htm?2/26/2466\">",
"     image 3",
"    </a>",
"    ). The presence of an AV canal defect in utero is associated with a 40 to 50 percent incidence of Down syndrome. Because of the high incidence of chromosomal abnormalities associated with this defect, fetal genetic analysis is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21118024\">",
"     'Trisomy 21'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Heart disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most often, AV canal defects are well tolerated in utero, with appropriate fetal growth and development. However, AV canal defects with severe AV valve regurgitation, or heart block associated with heterotaxy syndrome, may lead to nonimmune hydrops fetalis. In those cases, fetal echocardiography may be useful in determining the underlying cause of in utero heart failure and may also be used in monitoring transplacental therapy of heart failure",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonimmune hydrops fetalis\", section on 'Cardiovascular abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8312850\">",
"    <span class=\"h2\">",
"     Postnatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postnatal clinical presentation ranges from heart failure in patients with complete AV canal defects, or as an incidental cardiac physical finding in an asymptomatic patient with partial or transitional AV canal defects (",
"    <a class=\"graphic graphic_figure graphicRef86346 \" href=\"UTD.htm?25/5/25686\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370705\">",
"    <span class=\"h3\">",
"     Complete AV canal defect",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450999683\">",
"    <span class=\"h4\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of complete AV canal defect in infancy is heart failure due to excessive pulmonary blood flow and biventricular volume overload. Affected infants usually present with symptoms of tachypnea, poor feeding, growth retardation, sweating, and pallor around six weeks of age as pulmonary vascular resistance falls. The timing of symptoms in these patients is due to the significant delay in the normalization of pulmonary vascular resistance beyond the usual time frame of 7 to 10 days after birth in neonates without cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of heart failure is related to the size of the interventricular communication, ratio of pulmonary to systemic vascular resistance, and severity of AV valve regurgitation. Almost all uncorrected patients with AV canal defect will be symptomatic by one year of age.",
"   </p>",
"   <p>",
"    The following are common physical findings of a patient with complete AV canal defect and heart failure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperactive precordium with inferior and laterally displaced precordial impulse",
"     </li>",
"     <li>",
"      Increased pulmonary component of the second heart sound due to pulmonary artery hypertension",
"     </li>",
"     <li>",
"      Systolic ejection murmur heard at the left upper sternal border because of increased blood flow across the pulmonary valve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8315359\">",
"    <span class=\"h4\">",
"     Pulmonary vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with AV canal defect and pulmonary vascular disease, the intensity of the pulmonary outflow murmur decreases as a result of diminished blood flow across the pulmonary valve; however, the murmur due to AV valve regurgitation persists. Eventually, the progression of pulmonary vascular disease in unrepaired cases leads to irreversible pulmonary hypertension, presenting with systemic oxygen desaturation and cyanosis due to right-to-left shunting (ie, Eisenmenger syndrome). If heart failure symptoms do not develop by one year of age, premature development of pulmonary vascular obstructive disease should be suspected.",
"   </p>",
"   <p>",
"    Respiratory tract infections are common manifestations due to microatelectasis caused by increased pulmonary blood flow and interstitial pulmonary edema.",
"   </p>",
"   <p>",
"    In complete AV canal defect with tetralogy of Fallot, heart failure symptoms may be moderated by right ventricular outflow obstruction. If the degree of right ventricular obstruction increases, the pulmonary to systemic blood flow may become more balanced. Such infants may have good growth and development without signs and symptoms of heart failure. As the degree of obstruction increases and the pulmonary blood flow decreases, patients may become more cyanotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8315458\">",
"    <span class=\"h4\">",
"     Unbalanced AV canal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the AV canal defect is unbalanced, one ventricle receives most of the blood flow across the AV valve, resulting in hypoplasia of the other ventricle and, potentially, the corresponding great artery. Symptoms vary depending on which ventricle is affected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the left ventricle and its corresponding structures (eg, aortic valve and aortic arch) are hypoplastic, symptoms are related to low cardiac output (pale, diaphoresis, and dyspnea with absent femoral pulses) unless there is a large patent ductus arteriosus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Neonates'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H23884780#H23884780\">",
"       \"Etiology and diagnosis of heart failure in infants and children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the right ventricle is hypoplastic, cyanosis may be the predominant finding due to decreased blood flow to the lung and right-to-left shunting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8312866\">",
"    <span class=\"h3\">",
"     Partial and transitional AV canal defect presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with partial or transitional AV canal defect, shunting is predominantly left-to-right at the atrial level. Most patients do not present until adulthood when decreased left ventricular (LV) compliance leads to increased interatrial shunting and potential heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;Some patients may have symptoms of excess pulmonary blood flow, especially during exertion (eg, shortness of breath). Others will present with atrial fibrillation related to right atrial enlargement from the left-to-right shunt or left atrial enlargement from mitral regurgitation through an associated cleft. Asymptomatic patients may be identified during a routine physical examination because of an abnormal cardiac finding.",
"   </p>",
"   <p>",
"    The following physical findings are typically present in patients with a partial or transitional AV canal defect:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wide and fixed splitting of the second heart sound during respiration",
"     </li>",
"     <li>",
"      Systolic ejection murmur at the left upper sternal border with radiation to the lung fields due to increased blood flow across the pulmonary valve",
"     </li>",
"     <li>",
"      Increased right ventricular precordial impulse",
"     </li>",
"     <li>",
"      Diastolic rumble may be present as a result of increased blood flow across the tricuspid valve.",
"     </li>",
"     <li>",
"      Holosystolic murmur of mitral regurgitation related to a mitral valve cleft.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there is significant mitral valve regurgitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary overcirculation, symptoms of heart failure may develop earlier in life (eg, infancy). They include tachypnea, poor weight gain, and recurrent respiratory infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8312983\">",
"    <span class=\"h3\">",
"     Left AV valve regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of left AV valve regurgitation is present in patients with either complete or partial AV canal defects. In patients with significant regurgitation, physical findings include a high-pitched holosystolic murmur and a low-pitched mid-diastolic rumble, which usually are best heard at the cardiac apex. When regurgitation is directed towards the right atrium, the murmur radiates to the sternum and the diastolic rumble is heard at the right sternal border because of increased tricuspid flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8312975\">",
"    <span class=\"h2\">",
"     Tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients will undergo initial testing that includes electrocardiography and chest radiography. However, the diagnosis is generally confirmed by echocardiography. (See",
"    <a class=\"local\" href=\"#H6370743\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8313126\">",
"    <span class=\"h3\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both complete and partial AV canal defects, the cardiac silhouette is usually enlarged secondary to volume overload (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87173 \" href=\"UTD.htm?34/61/35792\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In partial AV canal defects, right atrial and ventricular enlargement and dilatation of main pulmonary artery are usually present because of increased pulmonary blood flow.",
"     </li>",
"     <li>",
"      Complete AV canal defects often demonstrate enlargement in all four cardiac chambers. Increased pulmonary markings are present in patients with a large left-to-right shunt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8313133\">",
"    <span class=\"h3\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with AV canal defects, the most characteristic electrocardiographic finding is a leftward and superior QRS axis in the frontal plane and counterclockwise depolarization pattern caused by posterior displacement of the atrioventricular node and His bundle (",
"    <a class=\"graphic graphic_figure graphicRef86336 \" href=\"UTD.htm?13/14/13543\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right atrial enlargement due to shunting either from the left atrium to right atrium or from the left ventricle to right atrium",
"     </li>",
"     <li>",
"      Prolongation of PR interval in some patients with atrial enlargement and increased conduction time [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/46\">",
"       46",
"      </a>",
"      ]",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      Right ventricular volume or pressure overload reflected as a rsR&rsquo; pattern in the right precordial leads",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy in the setting of significant left AV valve or common AV valve regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370743\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370752\">",
"    <span class=\"h2\">",
"     Fetal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine obstetric screening fetal four-chamber echocardiography can make an early in-utero diagnosis of atrioventricular (AV) canal defect (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86330 \" href=\"UTD.htm?2/26/2466\">",
"     image 3",
"    </a>",
"    ). The presence of a characteristic large defect at the crux of the heart that involves the atrial and ventricular septa, and the large common atrioventricular valve are key diagnostic features [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/47\">",
"     47",
"    </a>",
"    ]. However, antenatal detection rates remain lower than might be expected. In one study conducted in the United States, the demonstrated rate of detection of this lesion was less than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Another study from the United Kingdom showed that only 29 percent of live born infants were detected by routine obstetric ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When abnormalities are detected or suspected on the screening obstetric evaluation, the mother should be referred for specific fetal echocardiography. Detailed fetal echocardiography provides more precise information regarding the type of AV canal defect, any associated anatomic and hemodynamic abnormalities (especially AV valve regurgitation), and detection of any abnormality of the outflow tracts and the aortic or pulmonic valves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370759\">",
"    <span class=\"h2\">",
"     Postnatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal diagnosis of AV canal defects is generally confirmed by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/21,50,51\">",
"     21,50,51",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Echocardiography is performed based on a strong clinical suspicion for congenital heart disease (CHD) because of findings from a prenatal echocardiography, postnatal signs and symptoms of heart failure (eg, failure to thrive and tachypnea), and physical findings suggestive of cardiac disease (eg, heart murmur). (See",
"    <a class=\"local\" href=\"#H6370689\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8313342\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiographic diagnosis is made by identifying the characteristic AV septal and valvular defects.",
"    <strong>",
"    </strong>",
"    The apical or subcostal four-chamber views readily provide details of both atrial and ventricular septa using the internal crux as the imaging landmark (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86331 \" href=\"UTD.htm?13/28/13761\">",
"     image 5",
"    </a>",
"    ). Spectral and color-flow Doppler studies demonstrate the left-to-right shunts at the inferior border of the atrial septum and, in complete AV canal defects, the ventricular component. On occasion, an ostium primum defect can be confused with a dilated coronary sinus or an associated coronary sinus septal defect. Visualization of the floor of the left atrial cavity or roof of the coronary sinus, and the absence of turbulent flow across the coronary sinus, help to differentiate a primum atrial septal defect from an enlarged coronary sinus.",
"   </p>",
"   <p>",
"    In patients with complete AV canal defects, the subcostal, oblique angle demonstrates the common AV valve annulus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86333 \" href=\"UTD.htm?0/54/868\">",
"     image 6",
"    </a>",
"    ). Whereas, in patients with partial AV canal defects, short axis views from the parasternal or subcostal angles best visualize the mitral valve orifice, which is almost always abnormal and usually has a cleft between the superior and inferior leaflets.",
"   </p>",
"   <p>",
"    Due to the advances in echocardiography, cardiac catheterization is no longer the first-line modality to diagnose AV canal defects. Echocardiography is also used to determine additional anatomical and functional factors that impact on surgical management, which is discussed in the next section. Most children with AV canal defects can proceed to surgical repair after a complete two- and three-dimensional echocardiographic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983072\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation consists of additional echocardiographic imaging to help inform decisions regarding surgical management and timing of intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983263\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to confirming the diagnosis of an atrioventricular (AV) canal defect, two-dimensional echocardiography combined with Doppler echocardiography and three-dimensional echocardiography provide information needed for surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/50,54\">",
"     50,54",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    The echocardiographic evaluation should assess:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence and size of atrial and ventricular communications",
"     </li>",
"     <li>",
"      Direction of shunting",
"     </li>",
"     <li>",
"      AV valve morphology",
"     </li>",
"     <li>",
"      Orientation of the AV valve",
"     </li>",
"     <li>",
"      Relative sizes of the right and left ventricles",
"     </li>",
"     <li>",
"      Number and location of papillary muscles",
"     </li>",
"     <li>",
"      Left ventricular outflow obstruction",
"     </li>",
"     <li>",
"      Right ventricular outflow obstruction",
"     </li>",
"     <li>",
"      Additional atrial or ventricular septal defects",
"     </li>",
"     <li>",
"      Ventricular function",
"     </li>",
"     <li>",
"      Associated anomalies, such as abnormalities of systemic and pulmonary venous return or coarctation of the aorta",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983094\">",
"    <span class=\"h3\">",
"     AV valve morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, echocardiography detects the characteristic AV valve abnormalities in patients with AV canal defects. Further imaging defines that morphology and assesses the function of the abnormal valve.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete AV canal defects &ndash; Patients with complete defect have a common AV valve annulus that is composed of five leaflets. The chordal attachment of the superior bridging leaflet can be evaluated, allowing the noninvasive determination of the Rastelli classification of the common AV valve (see",
"      <a class=\"local\" href=\"#H450999445\">",
"       'Rastelli classification'",
"      </a>",
"      above). In parasternal long axis view, the valve is seen to open toward the ventricular septum, which is different than the normal appearance of opening toward the apex of the left ventricle. Color-flow Doppler studies show orientation, location, and degree of AV valve regurgitation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86334 \" href=\"UTD.htm?11/56/12166\">",
"       image 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Partial AV canal defects &ndash; In partial AV canal defects, the typically abnormal mitral valve is best visualized in short axis views from the parasternal or subcostal views. A cleft in the anterior mitral valve leaflet is best appreciated in a continuous short-axis sweep from the left ventricular apex to the aortic valve. Typically, the cleft in an AV canal defect is oriented toward the ventricular septum. In non-AV canal defects, the cleft is typically oriented toward the aortic valve [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/20\">",
"       20",
"      </a>",
"      ]. The apical and subcostal four chamber views also confirm that the AV valves are located at the same level in patients with partial AV canal defects as compared with patients with normal hearts where the tricuspid valve is apically displaced compared with the mitral valve.",
"      <br/>",
"      <br/>",
"      Three-dimensional echocardiographic images can be used to evaluate AV valve morphology, with an increased diagnostic accuracy compared with two-dimensional echocardiography",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      En face views by three-dimensional echocardiography from the left ventricle toward the mitral valve can image the length and extent of the cleft. En face views from above or below can detect the relative effective leaflet surface areas of the three components of the mitral valve",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/57\">",
"       57",
"      </a>",
"      ]. These views are similar to the surgeon&rsquo;s view at operation and can aid in surgical planning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983101\">",
"    <span class=\"h3\">",
"     Ventricular size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-dimensional echocardiography can easily diagnose the extreme forms of unbalanced complete AV canal defects. However, three-dimensional volume-based echocardiography detects the more subtle forms of unbalanced AV canal defects, which may have an impact on the decision to proceed with one- or two-ventricle repair [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H450999452\">",
"     'Balanced/unbalanced classification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/48?source=see_link&amp;anchor=H8314469#H8314469\">",
"     \"Management and outcome of atrioventricular (AV) canal defects\", section on 'Single ventricle palliation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983366\">",
"    <span class=\"h3\">",
"     Size of communication and shunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of ventricular shunting should be assessed from parasternal, apical, and subcostal locations. This is especially important in patients with transitional AV canal defects who typically have a small degree of ventricular shunting. In these patients, it is important to confirm that the ventricular septal defect is restrictive, since surgical repair is performed earlier when unrestrictive ventricular shunting is present. A high pressure gradient from left ventricle to right ventricle confirms the restrictive nature of the ventricular septal defect. A low velocity tricuspid regurgitation jet also confirms low right ventricular (RV) pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983108\">",
"    <span class=\"h3\">",
"     Papillary muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The papillary muscle orientation in AV canal defects is best visualized on short-axis imaging of the left ventricle. As previously discussed, papillary muscles are usually abnormal in size and location, and are associated with an increased risk of parachute mitral valve deformities and related mitral valve stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H90983938\">",
"     'Partial AV canal defect'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983115\">",
"    <span class=\"h3\">",
"     Left and right ventricular outflow tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcostal imaging demonstrates the typical elongation of the left ventricular outflow tract (LVOT), referred to as gooseneck deformity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86328 \" href=\"UTD.htm?14/7/14450\">",
"     image 1",
"    </a>",
"    ). In most cases, there is no LVOT obstruction.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H90983827\">",
"     'Left ventricular outflow tract'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Subcostal and parasternal short-axis imaging demonstrate the degree of infundibular narrowing of the right ventricular outflow tract (RVOT) when tetralogy of Fallot is present. In this view, assessment of the pulmonary arteries, including their confluence and their sizes, should also be performed.",
"   </p>",
"   <p>",
"    Continuous-wave Doppler evaluation reliably estimates combined dynamic and fixed pressure gradient, and is used to detect either left or right outflow obstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86335 \" href=\"UTD.htm?21/12/21700\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90983122\">",
"    <span class=\"h3\">",
"     Additional cardiovascular defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional secundum atrial septal defects and ventricular septal defects can be identified from subcostal and right parasternal views. Color-Doppler study can provide additional information in evaluating the amount and direction of shunting in such defects.",
"   </p>",
"   <p>",
"    A patent ductus arteriosus is a common finding associated with an AV canal defect that can be imaged directly from left parasternal, high left parasternal, and suprasternal locations. Color-flow Doppler evaluation effectively identifies the magnitude and direction of shunting. Although direction of shunting is usually left-to-right across the patent ductus arteriosus, in patients with severe pulmonary hypertension and elevated pulmonary vascular resistance, right-to-left shunt occurs at the ductal level. In these cases, it may be difficult to detect the presence and patency of the ductus arteriosus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370805\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative cardiac catheterization is rarely needed for routine anatomic delineation. Cardiac catheterization may be required for the assessment of pulmonary vascular resistance (PVR) in the older child when pulmonary vascular obstructive disease (PVOD) is suspected. Patients with elevated PVR should be evaluated to determine their PVR response to oxygen and specific pulmonary artery vasodilators, such as inhaled nitric oxide. Patients with a calculated PVR of 10 Wood",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or greater that does not fall below 5 to 7 Wood",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in response to vasodilators are at increased risk for death after surgical repair.",
"   </p>",
"   <p>",
"    Patients with Down syndrome have a higher ratio of pulmonary to systemic resistance compared with patients without Down syndrome, probably due to upper airway obstruction, hypoventilation, and sleep-apnea. This clinical difference usually resolves with 100 percent oxygen administration. For patients who have upper airway obstruction, endotracheal intubation and ventilation to a normal carbon dioxide level may be necessary to determine PVR accurately",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/34/11818/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H6370668\">",
"     'Pulmonary hypertension and Down syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173192218\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of complete atrioventricular (AV) canal defect includes other congenital cardiac conditions that cause early heart failure such as large ventricular septal defect (VSD). For partial AV canal defect, the differential diagnosis includes other cardiac conditions that result in atrial septal defects. Both complete and partial AV canal defects are distinguished from other cardiac diseases by echocardiography. (See",
"    <a class=\"local\" href=\"#H8313342\">",
"     'Echocardiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370907\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) canal defects consist of a group of congenital cardiac defects involving the AV septum and AV valves (ie, mitral and tricuspid valves).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AV canal defects account for about 4 to 5 percent of congenital heart defects with a prevalence of 0.19 per 1000 live births. (See",
"      <a class=\"local\" href=\"#H6370570\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Failure of the superior and inferior endocardial cushions to fuse correctly during cardiac development results in a broad range of AV septal and valve defects (",
"      <a class=\"graphic graphic_figure graphicRef86338 \" href=\"UTD.htm?39/23/40312\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef86346 \" href=\"UTD.htm?25/5/25686\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21118091\">",
"       'Anatomy of AV canal defects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H450999438\">",
"       'Complete, partial, intermediate, and transitional forms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete AV canal defect is caused by complete failure of fusion between the endocardial cushions resulting in both large atrial and ventricular septal defects, and a common AV valve.",
"     </li>",
"     <li>",
"      Partial AV canal defect is caused by incomplete or partial lack of fusion between the endocardial cushions resulting in a primum atrial septal defect, a single valve annulus with two separate AV valve orifices, and a cleft in the anterior mitral leaflet.",
"     </li>",
"     <li>",
"      Subtypes of complete AV canal defects include transitional (large primum defect, cleft mitral valve, and small inlet ventricular septal defect) and intermediate (in which a bridging tongue of tissue divides the common AV valve into two distinct orifices) AV canal defects. The transitional subtype has a similar physiology to that of a partial AV canal defect, as there is only a small degree of shunting at the ventricular level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a strong association between AV canal defects and trisomy 21 (also referred to as Down syndrome). Because of the high incidence of chromosomal abnormalities associated with this defect, we suggest that fetal genetic analysis be performed when an antenatal diagnosis of AV canal defect is made (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21118024\">",
"       'Trisomy 21'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete AV canal defects result in increased pulmonary blood flow because of left-to-right shunting at the atrial and ventricular levels (",
"      <a class=\"graphic graphic_figure graphicRef86346 \" href=\"UTD.htm?25/5/25686\">",
"       figure 1",
"      </a>",
"      ). Excessive pulmonary blood flow typically leads to heart failure, which presents with symptoms of tachypnea, sweating, and pallor. In younger patients, findings will also include poor feeding and growth retardation. Unrepaired defects will eventually cause elevated pulmonary vascular resistance and subsequent pulmonary artery hypertension. (See",
"      <a class=\"local\" href=\"#H1062508\">",
"       'Complete AV canal defect'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6370705\">",
"       'Complete AV canal defect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with partial and transitional AV canal defects (",
"      <a class=\"graphic graphic_figure graphicRef86346 \" href=\"UTD.htm?25/5/25686\">",
"       figure 1",
"      </a>",
"      ) may be asymptomatic until adulthood and present with a murmur noted on routine physical examination. Alternatively, adult patients may present with atrial fibrillation or findings of mitral valve regurgitation with or without heart failure symptoms (tachypnea, sweating, pallor, and fatigue). (See",
"      <a class=\"local\" href=\"#H6370675\">",
"       'Partial AV canal defect'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8312681\">",
"       'Transitional AV canal defect'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8312866\">",
"       'Partial and transitional AV canal defect presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial laboratory testing includes chest radiography with typical findings of cardiac enlargement and increased pulmonary markings, and electrocardiography with characteristic findings of a left and superior QRS axis and a counterclockwise depolarization pattern. (See",
"      <a class=\"local\" href=\"#H8312975\">",
"       'Tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AV canal defects are diagnosed by echocardiography with identification of the AV septal and valve defects. In-utero diagnosis can be made by routine antenatal echocardiographic screening. (See",
"      <a class=\"local\" href=\"#H6370743\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comprehensive echocardiographic evaluation provides additional delineation of the type of AV canal defect, and associated anatomic and hemodynamic abnormalities. This information is used to guide surgical management. (See",
"      <a class=\"local\" href=\"#H90983263\">",
"       'Echocardiography'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/3/48?source=see_link&amp;anchor=H173193611#H173193611\">",
"       \"Management and outcome of atrioventricular (AV) canal defects\", section on 'Overview of management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis of complete AV canal defects includes other congenital cardiac conditions that cause early heart failure such as large ventricular septal defect (VSD), and, for partial AV canal defects, other conditions with AV septal defects. AV canal defects are distinguished from these other cardiac diseases by echocardiography. (See",
"      <a class=\"local\" href=\"#H173192218\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8313342\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/1\">",
"      Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995; 16:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/2\">",
"      Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008; 153:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/3\">",
"      Cook AC, Allan LD, Anderson RH, et al. Atrioventricular septal defect in fetal life: a clinicopathological correlation. Cardiol Young 1991; 1:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/4\">",
"      Allan LD, Sharland GK, Milburn A, et al. Prospective diagnosis of 1,006 consecutive cases of congenital heart disease in the fetus. J Am Coll Cardiol 1994; 23:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/5\">",
"      Rosenthal GL, Wilson PD, Permutt T, et al. Birth weight and cardiovascular malformations: a population-based study. The Baltimore-Washington Infant Study. Am J Epidemiol 1991; 133:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/6\">",
"      Korenberg JR, Bradley C, Disteche CM. Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am J Hum Genet 1992; 50:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/7\">",
"      Agopian AJ, Moulik M, Gupta-Malhotra M, et al. Descriptive Epidemiology of Non-syndromic Complete Atrioventricular Canal Defects. Paediatr Perinat Epidemiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/8\">",
"      Rastelli G, Kirklin JW, Titus JL. Anatomic observations on complete form of persistent common atrioventricular canal with special reference to atrioventricular valves. Mayo Clin Proc 1966; 41:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/9\">",
"      Piccoli GP, Wilkinson JL, Macartney FJ, et al. Morphology and classification of complete atrioventricular defects. Br Heart J 1979; 42:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/10\">",
"      Bharati S, Kirklin JW, McAllister HA Jr, Lev M. The surgical anatomy of common atrioventricular orifice associated with tetralogy of Fallot, double outlet right ventricle and complete regular transposition. Circulation 1980; 61:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/11\">",
"      Sridaromont S, Feldt RH, Ritter DG, et al. Double-outlet right ventricle associated with persistent common atriventricular canal. Circulation 1975; 52:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/12\">",
"      Karl TR. Atrioventricular septal defect with tetralogy of Fallot or double-outlet right ventricle: surgical considerations. Semin Thorac Cardiovasc Surg 1997; 9:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/13\">",
"      Cohen MS, Jacobs ML, Weinberg PM, Rychik J. Morphometric analysis of unbalanced common atrioventricular canal using two-dimensional echocardiography. J Am Coll Cardiol 1996; 28:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/14\">",
"      VAN MIEROP LH, ALLEY RD, KAUSEL HW, STRANAHAN A. The anatomy and embryology of endocardial cushion defects. J Thorac Cardiovasc Surg 1962; 43:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/15\">",
"      Wenink AC, Zevallos JC. Developmental aspects of atrioventricular septal defects. Int J Cardiol 1988; 18:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/16\">",
"      Van Praagh S, Vangi V, Sul JH, et al. Tricuspid atresia or severe stenosis with partial common atrioventricular canal: anatomic data, clinical profile and surgical considerations. J Am Coll Cardiol 1991; 17:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/17\">",
"      Moran AM, Daebritz S, Keane JF, Mayer JE. Surgical management of mitral regurgitation after repair of endocardial cushion defects: early and midterm results. Circulation 2000; 102:III160.",
"     </a>",
"    </li>",
"    <li>",
"     Defects in cardiac septation. Atrioventricular Septal Defects. In: Echocardiography in Pediatric Heart Disease, 2nd ed, Snider AR, Ritter SB, Serwer GA (Eds), Mosby, 1997. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/19\">",
"      David I, Castaneda AR, Van Praagh R. Potentially parachute mitral valve in common atrioventricular canal: pathological anatomy and surgical importance. J Thorac Cardiovasc Surg 1982; 84:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/20\">",
"      Sigf&uacute;sson G, Ettedgui JA, Silverman NH, Anderson RH. Is a cleft in the anterior leaflet of an otherwise normal mitral valve an atrioventricular canal malformation? J Am Coll Cardiol 1995; 26:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/21\">",
"      Chin AJ, Bierman FZ, Sanders SP, et al. Subxyphoid 2-dimensional echocardiographic identification of left ventricular papillary muscle anomalies in complete common atrioventricular canal. Am J Cardiol 1983; 51:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/22\">",
"      Misumi H, Imai Y, Ishihara K, et al. Surgical treatment of double orifice mitral valve in atrioventricular septal defect. Nihon Ky��bu Geka Gakkai Zasshi 1993; 41:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/23\">",
"      Anderson RH, Baker EJ, Ho SY, et al. The morphology and diagnosis of atrioventricular septal defects. Cardiology in the Young 1991; 1:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/24\">",
"      Reeder GS, Danielson GK, Seward JB, et al. Fixed subaortic stenosis in atrioventricular canal defect: a Doppler echocardiographic study. J Am Coll Cardiol 1992; 20:386.",
"     </a>",
"    </li>",
"    <li>",
"     Bharati S, Lev M. Common atrioventricular orifice - Complete type. In: The Pathology of Congenital Heart Disease: A Personal Experience with More Than 6,300 Congenitally Malformed Hearts, Futura Publishing Company, Armonk 1996. p.553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/26\">",
"      Eisenberg LM, Markwald RR. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 1995; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/27\">",
"      Webb S, Anderson RH, Brown NA. Endocardial cushion development and heart loop architecture in the trisomy 16 mouse. Dev Dyn 1996; 206:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/28\">",
"      Boyer AS, Runyan RB. TGFbeta Type III and TGFbeta Type II receptors have distinct activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Dyn 2001; 221:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/29\">",
"      Ma L, Lu MF, Schwartz RJ, Martin JF. Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. Development 2005; 132:5601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/30\">",
"      Song L, Zhao M, Wu B, et al. Cell autonomous requirement of endocardial Smad4 during atrioventricular cushion development in mouse embryos. Dev Dyn 2011; 240:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/31\">",
"      Jiao K, Kulessa H, Tompkins K, et al. An essential role of Bmp4 in the atrioventricular septation of the mouse heart. Genes Dev 2003; 17:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/32\">",
"      Beppu H, Malhotra R, Beppu Y, et al. BMP type II receptor regulates positioning of outflow tract and remodeling of atrioventricular cushion during cardiogenesis. Dev Biol 2009; 331:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/33\">",
"      Lange AW, Molkentin JD, Yutzey KE. DSCR1 gene expression is dependent on NFATc1 during cardiac valve formation and colocalizes with anomalous organ development in trisomy 16 mice. Dev Biol 2004; 266:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/34\">",
"      Barlow GM, Chen XN, Shi ZY, et al. Down syndrome congenital heart disease: a narrowed region and a candidate gene. Genet Med 2001; 3:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/35\">",
"      Y��ld��r��m G, Gungorduk K, Yaz��c��o��lu F, et al. Prenatal diagnosis of complete atrioventricular canal defect: perinatal and neonatal outcomes. Obstet and Gynecol Int 2009; 2009:958.",
"     </a>",
"    </li>",
"    <li>",
"     Van Praagh SV. Cardiac malpositions and the heterotaxy syndromes. In: Nadas&rsquo; Pediatric Cardiology, 2nd ed, Keane JF, Lock JE, Fyler DC (Eds), Saunders Elsevier, Philadelphia 2006. p.675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/37\">",
"      Peoples WM, Moller JH, Edwards JE. Polysplenia: a review of 146 cases. Pediatr Cardiol 1983; 4:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/38\">",
"      Hals J, Hagemo PS, Thaulow E, S&oslash;rland SJ. Pulmonary vascular resistance in complete atrioventricular septal defect. A comparison between children with and without Down's syndrome. Acta Paediatr 1993; 82:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/39\">",
"      Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down's syndrome. N Engl J Med 1982; 307:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/40\">",
"      Newfeld EA, Sher M, Paul MH, Nikaidoh H. Pulmonary vascular disease in complete atrioventricular canal defect. Am J Cardiol 1977; 39:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/41\">",
"      Y��ld��r��m G, Gungorduk K, Yaz��c��o��lu F, et al. Prenatal diagnosis of complete atrioventricular septal defect: perinatal and neonatal outcomes. Obstet Gynecol Int 2009; 2009:958496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/42\">",
"      Kleinman CS, Donnerstein RL, DeVore GR, et al. Fetal echocardiography for evaluation of in utero congestive heart failure. N Engl J Med 1982; 306:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/43\">",
"      Rudolph AM. The changes in the circulation after birth. Their importance in congenital heart disease. Circulation 1970; 41:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/44\">",
"      SOMERVILLE J. OSTIUM PRIMUM DEFECT: FACTORS CAUSING DETERIORATION IN THE NATURAL HISTORY. Br Heart J 1965; 27:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/45\">",
"      Feldt RH, DuShane JW, Titus JL. The atrioventricular conduction system in persistent common atrioventricular canal defect: correlations with electrocardiogram. Circulation 1970; 42:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/46\">",
"      Fournier A, Young ML, Garcia OL, et al. Electrophysiologic cardiac function before and after surgery in children with atrioventricular canal. Am J Cardiol 1986; 57:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/47\">",
"      Machado MV, Crawford DC, Anderson RH, Allan LD. Atrioventricular septal defect in prenatal life. Br Heart J 1988; 59:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/48\">",
"      Allan LD. Atrioventricular septal defect in the fetus. Am J Obstet Gynecol 1999; 181:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/49\">",
"      ter Heide H, Thomson JD, Wharton GA, Gibbs JL. Poor sensitivity of routine fetal anomaly ultrasound screening for antenatal detection of atrioventricular septal defect. Heart 2004; 90:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/50\">",
"      Silverman NH, Zuberbuhler JR, Anderson RH. Atrioventricular septal defects: cross-sectional echocardiographic and morphologic comparisons. Int J Cardiol 1986; 13:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/51\">",
"      Cabrera A, Pastor E, Galdeano JM, et al. Cross-sectional echocardiography in the diagnosis of atrioventricular septal defect. Int J Cardiol 1990; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/52\">",
"      Lipshultz SE, Sanders SP, Mayer JE, et al. Are routine preoperative cardiac catheterization and angiography necessary before repair of ostium primum atrial septal defect? J Am Coll Cardiol 1988; 11:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/53\">",
"      Zellers TM, Zehr R, Weinstein E, et al. Two-dimensional and Doppler echocardiography alone can adequately define preoperative anatomy and hemodynamic status before repair of complete atrioventricular septal defect in infants &lt; 1 year old. J Am Coll Cardiol 1994; 24:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/54\">",
"      Smallhorn JF, Sutherland GR, Anderson RH, Macartney FJ. Cross-sectional echocardiographic assessment of conditions with atrioventricular valve leaflets attached to the atrial septum at the same level. Br Heart J 1982; 48:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/55\">",
"      Del Pasqua A, Sanders SP, de Zorzi A, et al. Impact of three-dimensional echocardiography in complex congenital heart defect cases: the surgical view. Pediatr Cardiol 2009; 30:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/56\">",
"      Takahashi K, Guerra V, Roman KS, et al. Three-dimensional echocardiography improves the understanding of the mechanisms and site of left atrioventricular valve regurgitation in atrioventricular septal defect. J Am Soc Echocardiogr 2006; 19:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/57\">",
"      Hlavacek AM, Crawford FA Jr, Chessa KS, Shirali GS. Real-time three-dimensional echocardiography is useful in the evaluation of patients with atrioventricular septal defects. Echocardiography 2006; 23:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/58\">",
"      van Son JA, Phoon CK, Silverman NH, Haas GS. Predicting feasibility of biventricular repair of right-dominant unbalanced atrioventricular canal. Ann Thorac Surg 1997; 63:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/59\">",
"      Cohen MS, Spray TL. Surgical management of unbalanced atrioventricular canal defect. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2005; :135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/34/11818/abstract/60\">",
"      Kohl T, Silverman NH. Comparison of cleft and papillary muscle position in cleft mitral valve and atrioventricular septal defect. Am J Cardiol 1996; 77:164.",
"     </a>",
"    </li>",
"    <li>",
"     Park JM, Ritter DG, Mair DD. Cardiac catheterization findings in persistent common atrioventricular canal. In: Atrioventricular Canal Defects, Feldt RH, McGoon DC, Ongley PA, et al (Eds), WB Saunders, Philadelphia 1976. p.76.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85595 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11818=[""].join("\n");
var outline_f11_34_11818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6370907\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6370563\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6370570\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450999423\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450999431\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450999438\">",
"      Complete, partial, intermediate, and transitional forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450999445\">",
"      Rastelli classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450999452\">",
"      Balanced/unbalanced classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6370577\">",
"      EMBRYOLOGY AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21118084\">",
"      Normal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21118091\">",
"      Anatomy of AV canal defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H779748176\">",
"      - AV valve abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H779748114\">",
"      Complete AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H90983938\">",
"      Partial AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90983827\">",
"      - Left ventricular outflow tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8312591\">",
"      - Associated cardiac defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11984932\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H779748217\">",
"      Molecular biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21118024\">",
"      Trisomy 21",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21118053\">",
"      Heterotaxy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6370661\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1062508\">",
"      Complete AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6370668\">",
"      - Pulmonary hypertension and Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6370675\">",
"      Partial AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8312681\">",
"      Transitional AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6370682\">",
"      AV valve regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6370689\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6370698\">",
"      Fetal presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8312850\">",
"      Postnatal presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6370705\">",
"      - Complete AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H450999683\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8315359\">",
"      Pulmonary vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8315458\">",
"      Unbalanced AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8312866\">",
"      - Partial and transitional AV canal defect presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8312983\">",
"      - Left AV valve regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8312975\">",
"      Tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8313126\">",
"      - Radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8313133\">",
"      - Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6370743\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6370752\">",
"      Fetal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6370759\">",
"      Postnatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8313342\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90983072\">",
"      FURTHER EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90983263\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90983094\">",
"      - AV valve morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90983101\">",
"      - Ventricular size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90983366\">",
"      - Size of communication and shunting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90983108\">",
"      - Papillary muscle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90983115\">",
"      - Left and right ventricular outflow tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90983122\">",
"      - Additional cardiovascular defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6370805\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173192218\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6370907\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/85595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85595|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/7/14450\" title=\"diagnostic image 1\">",
"      Gooseneck deformity of AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/12/21700\" title=\"diagnostic image 2\">",
"      Echo of AV canal defect and elongated LVOT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/26/2466\" title=\"diagnostic image 3\">",
"      Fetal echocardiogram AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/61/35792\" title=\"diagnostic image 4\">",
"      Chest radiograph of complete AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/28/13761\" title=\"diagnostic image 5\">",
"      2-D echocardiogram of AV canal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/54/868\" title=\"diagnostic image 6\">",
"      Echocardiogram of AV canal defect demonstrating common AV valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/56/12166\" title=\"diagnostic image 7\">",
"      Doppler echo of AV canal defect with AV valve regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85595|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/5/25686\" title=\"figure 1\">",
"      Different forms of AV canal defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29488\" title=\"figure 2\">",
"      Rastelli classification of AV canal defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/29/19923\" title=\"figure 3\">",
"      Development of the atrial septum primum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/23/40312\" title=\"figure 4\">",
"      Embryology of AV canal defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/14/13543\" title=\"figure 5\">",
"      ECG AV canal defect",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=related_link\">",
"      Etiology and diagnosis of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/48?source=related_link\">",
"      Management and outcome of atrioventricular (AV) canal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_34_11819="Intestinal dysmotility diabetes";
var content_f11_34_11819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Putative mechanisms of diabetic small bowel dysmotility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Due to autonomic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal small intestinal motility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial overgrowth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal colonic motility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorectal dysfunction - lowered rectal sensory threshold, weak internal anal sphincter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased intestinal secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exocrine pancreatic insufficiency (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Due to associated factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietetic foods - sorbitol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concurrent celiac sprue - similar genetic predisposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bile acid malabsorption (?)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11819=[""].join("\n");
var outline_f11_34_11819=null;
var title_f11_34_11820="Work-up for apparently H pylori-negative NSAID-negative ulcers";
var content_f11_34_11820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Work-up for apparently H. pylori-negative, NSAID-negative ulcers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Careful history",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comorbid disease",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Clinical evaluation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H. pylori that has escaped detection",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Perform at least two tests for H. pylori",
"         </li>",
"         <li>",
"          Ensure testing is performed while the patient is off of PPIs, antibiotics, bismuth",
"         </li>",
"         <li>",
"          Consider four duodenal mucosal biopsies to detect isolated duodenal colonization",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAIDs, aspirin, other potentially ulcerogenic drugs*",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Careful history",
"         </li>",
"         <li>",
"          Consider obtaining urine salicylate levels or platelet function tests to exclude surreptitious NSAID use",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasia, infection, infiltrative disease",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Biopsy ulcers and surrounding mucosa, including in the duodenum",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acid hypersecretion",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Measure basal acid output",
"         </li>",
"         <li>",
"          Measure serum gastrin levels off of PPIs",
"         </li>",
"         <li>",
"          Consider secretin stimulation in patients with normal serum gastrin levels",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic mechanisms",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Exclude use of crack cocaine and methamphetamine",
"         </li>",
"         <li>",
"          Consider angiography",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H. pylori: Helicobacter pylori; NSAID: nonsteroidal antiinflammatory drug; PPI: proton pump inhibitor.",
"     <br>",
"      * See table \"Causes of peptic ulcer disease\".",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30:791.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11820=[""].join("\n");
var outline_f11_34_11820=null;
var title_f11_34_11821="Surv unkn primary ca";
var content_f11_34_11821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival of all patients* with unknown primary cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Study",
"      </td>",
"      <td class=\"subtitle1\">",
"       No. of patients",
"      </td>",
"      <td class=\"subtitle1\">",
"       Median (mo)",
"      </td>",
"      <td class=\"subtitle1\">",
"       1-year (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       5-year (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yale University",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td>",
"       1268",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M.D. Anderson",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"      <td>",
"       1000",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       11",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       University of Kansas",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"      <td>",
"       686",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       21.5",
"      </td>",
"      <td>",
"       5.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Charity Hospital",
"       <sup>",
"        [4]",
"       </sup>",
"      </td>",
"      <td>",
"       453",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       13.9",
"      </td>",
"      <td>",
"       3.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Johns Hopkins",
"       <sup>",
"        [5]",
"       </sup>",
"      </td>",
"      <td>",
"       245",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mayo Clinic",
"       <sup>",
"        [6]",
"       </sup>",
"      </td>",
"      <td>",
"       150",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       0.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       SEER",
"       <sup>",
"        [7]",
"       </sup>",
"      </td>",
"      <td>",
"       26,050",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Southeast Netherlands",
"       <sup>",
"        [8]",
"       </sup>",
"      </td>",
"      <td>",
"       1024",
"      </td>",
"      <td>",
"       2.75",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Switzerland",
"       <sup>",
"        [9]",
"       </sup>",
"      </td>",
"      <td>",
"       543",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total",
"      </td>",
"      <td>",
"       31,419",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported; SEER: Surveillance, Epidemiology, and End Results registries.",
"     <br>",
"      * Includes treated and untreated patient groups, all histologies, and clinical presentations.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57:120.",
"     <br>",
"      2. Hess KR, Abbruzzese MC, Lenzi R, et al. Classification and regression free analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5:3403.",
"      <br>",
"       3. Holmes FT, Fouts TL. Metastatic cancer of unknown primary site. Cancer 1970; 26:816.",
"       <br>",
"        4. Krementz ET, Cerise EJ, Foster DC, et al. Metastases of undetermined source. Curr Probl Cancer 1979; 4:1.",
"        <br>",
"         5. Markman M. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at the Johns Hopkins Hospital from 1965-1979. Med Pediatr Oncol 1982; 10:569.",
"         <br>",
"          6. Moertel CG, Reitmeier RJ, Schutt AJ, et al. Treatment of the patient with adenocarcinoma of unknown primary site. Cancer 1972; 30:1469.",
"          <br>",
"           7. Muir C. Cancer of unknown primary site . Cancer 1995; 75:353.",
"           <br>",
"            8. Van de Wouw AJ, Janssen-Heijnen MLC, Coebergh JWW, et al. Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherlands 1984-1992. Eur J Cancer 2002; 38:409.",
"            <br>",
"             9. Levi F, Te VC, Erler G, et al. Epidemiology of unknown primary tumors. Eur J Cancer 2002; 38:1810.",
"             <br>",
"              Reproduced with permission from: Greco, FA, Hainsworth, JD. Cancer of Unknown Primary site. In: Cancer: Principles and Practice of Oncology 8th edition, DeVita, VT, Lawrence, TS, Rosenberg, SA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11821=[""].join("\n");
var outline_f11_34_11821=null;
var title_f11_34_11822="Mycosis fungoides TNMB classification";
var content_f11_34_11822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mycosis Fungoides Cooperative Group TNMB classification of cutaneous T-cell lymphoma (CTCL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Skin (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"       <td>",
"        Limited patches*, papules, and/or plaques",
"        <sup>",
"         &bull;",
"        </sup>",
"        covering &lt;10 percent of the skin surface; may further stratify into T",
"        <sub>",
"         1a",
"        </sub>",
"        (patch only) versus T",
"        <sub>",
"         1b",
"        </sub>",
"        (plaque &plusmn; patch)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        Patches, papules, or plaques covering &ge;10 percent of the skin surface; may further stratify into T",
"        <sub>",
"         2a",
"        </sub>",
"        (patch only) versus T",
"        <sub>",
"         2b",
"        </sub>",
"        (plaque &plusmn; patch)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"       <td>",
"        One or more tumors",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (&ge;1 cm diameter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        Confluence of erythema covering &ge;80 percent body surface area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Node (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        No clinically abnormal lymph nodes",
"        <sup>",
"         &loz;",
"        </sup>",
"        ; biopsy not required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        N",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Clinically abnormal lymph nodes; histopathology Dutch grade 1 or NCI LN0-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N",
"        <sub>",
"         1a",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone negative",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N",
"        <sub>",
"         1b",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone positive",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        N",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Clinically abnormal lymph nodes; histopathology Dutch grade 2 or NCI LN3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N",
"        <sub>",
"         2a",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone negative",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N",
"        <sub>",
"         2b",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone positive",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"       <td>",
"        Clinically abnormal lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N",
"        <sub>",
"         X",
"        </sub>",
"       </td>",
"       <td>",
"        Clinically abnormal lymph nodes; no histologic confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Visceral (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        No visceral organ involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"       <td>",
"        Visceral involvement (must have pathology confirmation",
"        <sup>",
"         &yen;",
"        </sup>",
"        and organ involved should be specified)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Blood (B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        No significant blood involvement: &le;5 percent of S&eacute;zary cells. For clinical trials, B",
"        <sub>",
"         0",
"        </sub>",
"        may also be defined as &lt;250/microL S&eacute;zary cells; CD4+CD26- or CD4+CD7- cells or CD4+CD26- and CD4+CD7- cells &lt;15 percent by flow cytrometry.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        B",
"        <sub>",
"         0a",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        B",
"        <sub>",
"         0b",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Low blood tumor burden: Does not meet the criteria of B",
"        <sub>",
"         0",
"        </sub>",
"        or&nbsp;B",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        B",
"        <sub>",
"         1a",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        B",
"        <sub>",
"         1b",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clone positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        High blood tumor burden: Positive clone",
"        <sup>",
"         ������",
"        </sup>",
"        plus one of the following: &ge;1000/microL&nbsp;S&eacute;zary cells; CD4/CD8 &ge;10; CD4+CD7- cells &ge;40 percent; or CD4+CD26- cells &ge;30 percent. For clinical trials, B",
"        <sub>",
"         2",
"        </sub>",
"        may also be defined as &gt;1000/microL CD4+CD26- or CD4+CD7- cells.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For skin, patch indicates any size lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      For skin, plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikilderma should be noted. Histologic features such as folliculotropism or large-cell transformation (&gt;25 percent large cells), CD30+ or CD30-, and clinical features such as ulceration are important to document.",
"      <br>",
"       &Delta; For skin, tumor indicates at least one 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note if histologic evidence of large-cell transformation has occurred. Phenotyping for CD30 is encouraged.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        For node, abnormal lymph node(s) indicates any lymph node that on physical examination is firm, irregular, clustered, fixed, or 1.5 cm or larger in diameter or on imaging is &gt;1.5 cm in the long axis or &gt;1 cm in the short axis. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal.",
"        <br>",
"         &sect; A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene.",
"         <br>",
"          &yen; For viscera, spleen and liver may be diagnosed by imaging criteria alone.",
"          <br>",
"           &Dagger; The clone in the blood should match that of the skin. The relevance of an isolated clone in the blood or a clone in the blood that does not match the clone in the skin remains to be determined.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713. Copyright &copy; the American Society of Hematology.",
"     <br>",
"      Additional data from:&nbsp;Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11822=[""].join("\n");
var outline_f11_34_11822=null;
var title_f11_34_11823="Tilted disc";
var content_f11_34_11823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tilted disc",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the oblong, tilted, more elliptical shape.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_34_11823=[""].join("\n");
var outline_f11_34_11823=null;
              